

Quarterly Disclosure Report

For the Six Months Ended December 31, 2018

(Unaudited)

Peter J. McCanna
President and Interim Chief Financial Officer
Baylor Scott & White Health
214-820-7506
Peter.McCanna@BSWHealth.org

www.BaylorScottandWhite.com

Quarterly Disclosure Report for December 31, 2018

BAYLOR SCOTT & WHITE HEALTH

**NOTICE
relating to:**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(BAYLOR HEALTH CARE SYSTEM PROJECT)
SERIES 2011A**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(BAYLOR HEALTH CARE SYSTEM PROJECT)
SERIES 2011B
7 MONTH WINDOW VRDB**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(BAYLOR HEALTH CARE SYSTEM PROJECT)
SERIES 2011C**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(BAYLOR HEALTH CARE SYSTEM PROJECT)
SERIES 2013A**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(BAYLOR HEALTH CARE SYSTEM PROJECT)
SERIES 2013B
7 MONTH WINDOW VRDB**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
TAXABLE HOSPITAL REVENUE BONDS
(BAYLOR HEALTH CARE SYSTEM PROJECT)
SERIES 2013C**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(SCOTT & WHITE HEALTHCARE PROJECT)
SERIES 2013A**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(SCOTT & WHITE HEALTHCARE PROJECT)
SERIES 2013C**

**BAYLOR SCOTT & WHITE HOLDINGS
TAXABLE BONDS
SERIES 2015**

**BAYLOR SCOTT & WHITE HOLDINGS
TAXABLE BONDS
SERIES 2016**

**TARRANT COUNTY CULTURAL EDUCATION
FACILITIES FINANCE CORPORATION
HOSPITAL REVENUE BONDS
(BAYLOR SCOTT & WHITE HEALTHCARE PROJECT)
SERIES 2016A**

**BAYLOR SCOTT & WHITE HOLDINGS
TAXABLE COMMERCIAL PAPER NOTES
SERIES A**

Quarterly Disclosure Report for December 31, 2018

CUSIP No.'s:

87638QFN4,	87638QFP9,	87638QFK0,	87638QFL8,	87638QFQ7,	87638QFR5,	87638QFS3,
87638QFM6,	87638QFT1,	87638QFX2,	87638QEW5,	87638QGU7,	87638QGV5,	87638QGW3,
87638QHA0,	87638QGX1,	87638QGY9,	87638QGZ6,	87638QGT0,	87638QHB8,	072863AA1,
072863AB9,	072863AC7,	072863AD5,	072863AE3,	072863AF0,	87638QNV7,	87638QNW5,
87638QNX3,	87638QNY1,	87638QNZ8,	87638QPA1,	87638QPB9,	87638QPC7,	87638QPD5,
87638QPE3,	87638QPF0,	87638QPG8,	87638QPH6,	87638QPJ2,	87638QPK9,	87638QPL7,
87638QPM5,	87638QPN3,	87638QPQ6,	87638QPR4,	87638QPP8,	87638QGC7,	87638QGD5,
87638QGE3,	87638QGF0,	87638QGG8,	87638QGH6,	87638QGJ2,	87638QGK9,	87638QGL7,
87638QGM5,	87638QGN3,	87638QGQ6,	87638QGP8,	87638QGR4		

Commercial Paper Base CUSIP No.'s:

07287B	07287C	07287D
--------	--------	--------

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

TABLE OF CONTENTS

ORGANIZATION	Page 2
KEY OPERATING AND FINANCIAL INDICATORS	Page 7
FINANCIAL OPERATIONS SUMMARY	Page 7
MANAGEMENT DISCUSSION AND ANALYSIS:	
Net Operating Income	Page 9
Total Operating Revenue	Page 9
Total Operating Expenses	Page 9
Full-Time Equivalents	Page 11
Nonoperating Gains (Losses)	Page 11
Utilization Statistics	Page 12
Liquidity	Page 17
NET ASSETS OF THE FOUNDATIONS	Page 19
COMBINED BALANCE SHEETS	Page 20
COMBINED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS	Page 22
COMBINED STATEMENTS OF CASH FLOWS	Page 24
NOTES TO COMBINED FINANCIAL STATEMENTS	Page 25
SUPPLEMENTARY COMBINING FINANCIAL INFORMATION OF THE OBLIGATED AFFILIATES AND BSWH	
Combining Balance Sheets	Page 49
Combining Statements of Operations and Changes in Net Assets	Page 51
Obligated Affiliates – Combined Statement of Cash Flows	Page 53

Quarterly Disclosure Report for December 31, 2018

ATTENTION

This document is marked with a dated date of December 31, 2018 and reflects information only as of that dated date. Readers are cautioned not to assume that any information has been updated beyond the dated date except as to any portion of the document that expressly states that it constitutes an update concerning specific recent events occurring after the dated date of the document. Any information contained in the portion of the document indicated to concern recent events speaks only as of its date. We expressly disclaim any duty to provide an update of any information contained in this document.

The information contained in this document may include “forward-looking statements” by using forward-looking words such as “may,” “will,” “should,” “expects,” “believes,” “anticipates,” “estimates,” or others. You are cautioned that forward-looking statements are subject to a variety of uncertainties that could cause actual results to differ from the projected results. Those risks and uncertainties include general economic and business conditions, receipt of funding grants, and various other factors which are beyond our control.

Because we cannot predict all factors that may affect future decisions, actions, events, or financial circumstances, what actually happens may be different from what we include in forward-looking statements.

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

ORGANIZATION

Baylor Scott & White Health System

Baylor Scott & White Holdings (BSW Holdings), a Texas nonprofit corporation, and its controlled affiliates (collectively, the “System” or “BSWH”) were created from the combination of two Texas health care systems, Baylor Health Care System (BHCS) and its controlled affiliates and Scott & White Healthcare (S&W) and its controlled affiliates. BSW Holdings and Baylor Scott & White Health (BSW Health), a Texas nonprofit corporation, were created by BHCS and S&W in connection with their combination. BSW Holdings is the sole member of BHCS, S&W, and BSW Health and has control and substantial reserved powers over all BHCS and S&W controlled affiliates.

The System includes two flagship hospitals, Baylor University Medical Center (BUMC) and Scott & White Memorial Hospital, now doing business as Baylor Scott & White Medical Center - Temple (SWMH), along with twenty-two other hospitals (see “BSWH Adult and Pediatric Licensed Beds” table) located in north and central Texas, excluding joint venture hospitals noted below.

The System includes five foundations and one research institute which are the Baylor Health Care System Foundation, Scott & White Healthcare Foundation, Irving Healthcare Foundation, All Saints Health Foundation, Scott & White Healthcare Foundation Brenham, and Baylor Scott & White Health Research Institute.

The System also includes Baylor Scott & White Quality Alliance (BSWQA). BSWQA is an accountable care organization functioning as a clinically integrated health network of employed physicians, independent physicians, hospitals, and other providers of care who are committed to delivering high quality, cost-effective, value-based care.

The System also includes Scott & White Clinic (the “Clinic”), HealthTexas Provider Network (HTPN), Hillcrest Family Health Center, and Hillcrest Physician Services. The Clinic, a Texas nonprofit corporation, operates clinics located throughout the central Texas area, in addition to the main campus in Temple, Texas. HTPN is a Texas nonprofit corporation that owns and operates primary care and specialty practices in the Dallas-Fort Worth metroplex and north Texas. Hillcrest Family Health Center and Hillcrest Physician Services operate clinics in the greater Waco area.

The System operates Scott and White Health Plan and its subsidiary, Insurance Company of Scott and White (collectively referred to as the “Health Plan”), which provides health insurance benefits to approximately 226,000 members through a variety of commercial, Medicaid, Medicare, Part D, Pharmacy Benefits Management, and Administrative Services Only products and services.

Quarterly Disclosure Report for December 31, 2018

The System's combined financial statements also include partnerships through Texas Health Ventures Group, LLC (THVG JV) with ten short-stay surgery hospitals and twenty-eight ambulatory surgery centers, BIR JV, LLP (BIR JV) with four rehabilitation hospitals and ninety-three clinics, EBD JV, LLP (EBD JV) with eight emergency medical centers, ESWCT, LLC that operates one emergency medical center, BTDI JV, LLP (BTDI JV) with thirty-eight imaging centers, and THVG Bariatric, LLC (THVGB), which has provided bariatric services.

The System is committed to medical education in support of its mission of exemplary care, education, and research. The Texas A&M College of Medicine and the System have established Clinical Training Programs, for which medical students complete clinical rotations at BUMC and SWMH. Central Texas Veterans Health Care System is a major clinical partner in Temple and helps to train the System's residents and medical students. Because of this affiliation, the System's trainees are able to better identify the needs of veterans and their families. Nursing education is conducted through programs and affiliations with numerous schools of nursing including Baylor University School of Nursing, Dallas County Community College District, Texas A&M University-Corpus Christi, Texas Woman's University, University of Mary Hardin-Baylor, and the University of Texas at Arlington. A number of these students remain with the System as employees following their training and education.

Obligated Group

BSW Holdings and certain of its affiliates issue and secure debt ("Master Debt") under a Master Indenture of Trust and Security Agreement, dated as of February 1, 2014, as supplemented and amended (the "Master Indenture"), among BSW Holdings, the affiliates from time to time obligated thereunder (the "Obligated Affiliates"), and The Bank of New York Mellon Trust Company, National Association, as trustee. The following entities are currently Obligated Affiliates:

- BSW Holdings
- BSW Health
- BHCS, a Texas nonprofit corporation
- S&W, a Texas nonprofit corporation
- BUMC, a Texas nonprofit corporation
- Baylor All Saints Medical Center, a Texas nonprofit corporation, doing business as Baylor Scott & White All Saints Medical Center – Fort Worth
- Baylor Regional Medical Center at Grapevine, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – Grapevine
- Baylor Medical Center at Waxahachie, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – Waxahachie
- Baylor Regional Medical Center at Plano, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – Plano
- SWMH, a Texas nonprofit corporation, also doing business as Baylor Scott & White McLane Children's Medical Center

Quarterly Disclosure Report for December 31, 2018

- Scott & White Clinic, a Texas nonprofit corporation
- Scott & White Hospital – Round Rock, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – Round Rock and Baylor Scott & White Medical Center – Lakeway
- Scott & White Continuing Care Hospital, a Texas nonprofit corporation, doing business as Baylor Scott & White Continuing Care Hospital
- Hillcrest Baptist Medical Center, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – Hillcrest
- Baylor Medical Centers at Garland and McKinney, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – McKinney
- Scott & White Hospital – College Station, a Texas nonprofit corporation, doing business as Baylor Scott & White Medical Center – College Station

BSW Holdings is currently the Combined Group Representative under the Master Indenture. There are currently no Designated Affiliates under the Master Indenture.

The combined System's credit ratings are Aa3 (Stable Outlook) by Moody's Investors Service and AA- (Stable Outlook) by S&P Global Ratings.

Awards and Distinctions

The System is recognized as one of the leading health care delivery systems across the United States, having received the following recognitions, among others:

- *U.S. News & World Report* – According to U.S. News & World Report's "Best Hospitals" and "Best Hospitals for Common Care" 2017-2018 ratings, 13 Baylor Scott & White Health hospitals received recognition. This includes four nationally ranked hospitals and two hospitals in the Texas Top Ten, the most of any health system in Texas.
- *Becker's Hospital Review* – Listed among the 150 Top Places to Work in Healthcare.
- *Fortune and Great Place to Work* – Listed among the Best Work Places in Health Care by Fortune and the Great Place to Work Institute for the second year in a row.
- Eighty HTPN practices and fifty-one S&W clinics have received the National Committee for Quality Assurance ("NCQA") Patient-Centered Medical Home Recognition for using evidence-based, patient-centered processes that focus on highly coordinated care and long-term, participative relationships.
- *Press Ganey* – 11 hospitals earned the Press Ganey Guardian of Excellence Award, which recognizes top-performing health care facilities that have consistently rated in the 95th percentile or above for patient experience based on one year of data. Additionally, 3 hospitals earned the Pinnacle of Excellence Award.

Quarterly Disclosure Report for December 31, 2018

BUMC

- *U.S. News & World Report* – BUMC is ranked as the No. 2 hospital in the Dallas metro area, as well as No. 3 in Texas, and was nationally recognized for the 25th consecutive year.
- *U.S. News & World Report* – Named as one of the top 50 hospitals nationally in two medical specialties: Ear, Nose & Throat and Gastroenterology & GI Surgery, and high performing in Cancer, Diabetes & Endocrinology, Geriatrics, Neurology and Neurosurgery, Nephrology, Orthopedics, and Pulmonology.
- *The Joint Commission* – Reaccredited with a Gold Seal of Approval™ for the Ventricular Assist Device Program, the nation's first such accredited program.
- *Extracorporeal Life Support Organization (ESLO)* - Gold Level Award for Excellence in Life Support – BUMC is the first and only adult extracorporeal membrane oxygenation (ECMO) center in north Texas to earn this award.

SWMH

- *U.S. News & World Report* – Ranked among top 10 hospitals in Texas; nationally ranked in Ear, Nose and Throat care; high performing in two specialties – Gastroenterology & GI Surgery, and Pulmonology; high performing in four common procedures or conditions – heart failure, colon cancer surgery, COPD (chronic obstructive pulmonary disease), and knee replacement.
- *Becker's Hospital Review* – 100 Hospitals and Health Systems with Great Oncology Programs in U.S. for Glenda Tanner Vasicek Cancer Center.
- *American Heart Association/American Stroke Association* – Get with the Guidelines®– Stroke GOLD PLUS Target; Stroke Elite Plus Quality Achievement Award.
- *American Heart Association* – Mission: Lifeline® STEMI Receiving Center – GOLD Plus Achievement Award Hospital.
- *American Heart Association* – Mission: Lifeline® NSTEMI – Bronze Achievement Award.
- *The Joint Commission* – The Gold Seal of Approval; Accredited Programs in Hospital, Nursing Care Center, Home Care; Advanced Certification in Stroke (Primary Stroke Center) and Ventricular Assist Device.

Quarterly Disclosure Report for December 31, 2018

BSWQA

- *NCQA ACO Accreditation: Level 2* – Verifies BSWQA has the infrastructure to support value-based delivery and the accountability.
- *NCQA Patient-Centered Medical Home Recognition* – 146 practices representing 655 providers.
- *Becker's Hospital Review* – Named to Becker's Top 110 ACOs to Know in 2018.
- *NCQA Case Management Accreditation* – The National Committee for Quality Assurance (NCQA) awarded BSWQA 3-year Accreditation for its Case Management program, effective December 19, 2017 – December 19, 2020. This Accreditation verifies that BSWQA has a process in place to ensure safe transitions.
- *NAACOS "Innovation" Award* – Honors BSWQA's improvements in the percentage of providers meeting or exceeding focus measures.

Health Plan

- Every year, Medicare evaluates plans based on a 5-star rating system. The Health Plan's SeniorCare (Cost) HMO received an overall 4.5 out of 5 stars from the Centers for Medicare & Medicaid Services for 2018. SeniorCare Advantage HMO, which was first offered in 2018, also now bears the 4.5 out of 5 star rating, as the SeniorCare (Cost) membership was passively enrolled into the SeniorCare Advantage HMO effective January 1, 2019. Due to this star rating, the Health Plan was recently recognized as one of the 2019 Best Insurance Companies for Medicare Advantage by U.S. News & World Report – making it one of only two Medicare providers in Texas to be included on this prestigious list.
- The Health Plan is consistently rated one of the top health plans in Texas by NCQ's Private Health Insurance Plan Ratings.

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

KEY OPERATING AND FINANCIAL INDICATORS

The information contained in this document represents the financial condition and results of operations of BSWH for fiscal years ending June 30, 2018 and 2017, and the six months ended December 31, 2018 and 2017.

BSWH Key Operating and Financial Indicators				
(\$ Thousands)				
	Year Ended June 30,		Six Months Ended December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
Total operating revenue	\$ 9,084,476	\$ 9,476,624	\$ 4,813,562	\$ 4,909,417
Operating margin	3.2%	6.1%	8.0%	8.5%
Adjusted EBITDA ⁽¹⁾	\$ 888,767	\$ 1,244,121	\$ 730,496	\$ 731,347
Cash and investments	\$ 5,268,661	\$ 5,770,844	\$ 5,566,737	\$ 5,561,761
Days in patient accounts receivable ⁽²⁾	38.5	36.0	39.1	37.1

(1) Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) is defined as revenue in excess of expenses plus depreciation, amortization, taxes, interest, excluding unrealized gains/losses on investments, unrealized gains/losses on interest rate swaps, and loss on extinguishment of debt.

(2) Days in Patient Accounts Receivable is defined as net patient receivables divided by average daily net patient care revenue. Average daily net patient revenue is defined as net patient care revenue (less patient related bad debt) divided by the number of days in the period.

FINANCIAL OPERATIONS SUMMARY

BSWH Summary Combined Balance Sheets				
(\$ Thousands)				
	June 30,		December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
ASSETS				
Current assets	\$ 2,840,871	\$ 2,992,900	\$ 3,041,856	\$ 2,813,107
Long-term investments	3,562,260	4,024,716	3,785,973	4,134,039
Assets whose use is limited	324,526	302,997	340,982	287,248
Property and equipment, net	3,525,384	3,683,590	3,577,277	3,768,179
Other assets	893,565	1,133,858	1,130,581	1,137,769
Total assets	<u>\$ 11,146,606</u>	<u>\$ 12,138,061</u>	<u>\$ 11,876,669</u>	<u>\$ 12,140,342</u>
LIABILITIES AND NET ASSETS				
Current liabilities	\$ 1,422,380	\$ 1,797,414	\$ 1,573,148	\$ 1,640,607
Long-term debt and capital lease obligations less current maturities	3,171,837	3,087,064	3,062,642	3,121,040
Other long-term liabilities	670,301	635,141	674,562	656,274
Total liabilities	<u>5,264,518</u>	<u>5,519,619</u>	<u>5,310,352</u>	<u>5,417,921</u>
Noncontrolling interests - redeemable	443,128	424,704	510,049	449,577
Net assets	<u>5,438,960</u>	<u>6,193,738</u>	<u>6,056,268</u>	<u>6,272,844</u>
Total liabilities and net assets	<u>\$ 11,146,606</u>	<u>\$ 12,138,061</u>	<u>\$ 11,876,669</u>	<u>\$ 12,140,342</u>

Quarterly Disclosure Report for December 31, 2018

BSWH Summary Combined Statements of Operations

(\$ Thousands)

	Year Ended June 30,		Six Months Ended December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
	Total operating revenue	\$ 9,084,476	\$ 9,476,624	\$ 4,813,562
Total operating expenses	<u>8,792,603</u>	<u>8,894,336</u>	<u>4,430,190</u>	<u>4,493,660</u>
Income from operations	291,873	582,288	383,372	415,757
Nonoperating gains and income tax expense	<u>338,582</u>	<u>258,771</u>	<u>212,124</u>	<u>(148,093)</u>
Excess of revenues over expenses	<u>\$ 630,455</u>	<u>\$ 841,059</u>	<u>\$ 595,496</u>	<u>\$ 267,664</u>

BSWH Summary Financial Information

(\$ Thousands)

	Year Ended June 30,		Six Months Ended December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
	CASH FLOW			
Cash flow from operating activities	\$ 750,189	\$ 1,204,704	\$ 542,413	\$ 432,354
Adjusted operating cash flow ⁽¹⁾	\$ 793,144	\$ 1,083,089	\$ 631,785	\$ 675,616
Adjusted EBITDA ⁽²⁾	\$ 888,767	\$ 1,244,121	\$ 730,496	\$ 731,347
Capital expenditures for property and equipment	\$ 406,207	\$ 485,271	\$ 218,553	\$ 268,233
Total capitalization ⁽³⁾	\$ 8,164,839	\$ 8,863,978	\$ 8,705,823	\$ 9,017,241
FINANCIAL RATIOS				
Operating margin	3.2%	6.1%	8.0%	8.5%
Adjusted operating cash flow as a percentage of total revenue ⁽¹⁾	8.7%	11.4%	13.1%	13.8%
Adjusted EBITDA margin ⁽⁴⁾	9.8%	13.1%	15.2%	14.9%
Debt to capitalization ⁽⁵⁾	40.0%	38.0%	38.4%	38.0%
Debt to cash flow ⁽⁶⁾	4.4x	3.2x	2.6x	2.7x

(1) Adjusted operating cash flow is defined as income from operations plus depreciation and amortization plus interest expense. Adjusted operating cash flow as a percentage of total revenue is calculated by dividing the adjusted operating cash flow by total operating revenue.

(2) Adjusted EBITDA is defined as revenue in excess of expenses plus depreciation, amortization, taxes, interest, excluding unrealized gains/losses on investments, unrealized gains/losses on interest rate swaps and loss on extinguishment of debt.

(3) Total capitalization is defined as long-term debt (including long-term debt subject to remarketing arrangements and commercial paper net of current maturities) plus unrestricted net assets.

(4) Adjusted EBITDA margin is defined as Adjusted EBITDA divided by total operating revenue.

(5) Debt to capitalization is defined as long-term debt (including long-term debt subject to remarketing arrangements and commercial paper net of current maturities) divided by total capitalization.

(6) Debt to cash flow is defined as long-term debt (including long-term debt subject to remarketing arrangements and commercial paper plus current maturities) divided by (excess of revenues over expenses, plus depreciation and amortization, excluding unrealized gains/losses on investments, and unrealized gains/losses on interest rate swaps divided by number of days in the period times 365).

Quarterly Disclosure Report for December 31, 2018

MANAGEMENT DISCUSSION AND ANALYSIS

Net Operating Income

The System's operating margin for the first six months of fiscal year 2019 was \$415.8 million or 8.5% of total operating revenue, compared to \$383.4 million or 8.0% for the first six months of fiscal year 2018. Adjusted EBITDA was \$731.3 million or 14.9% of total operating revenue for the first six months of fiscal year 2019 compared to \$730.5 million or 15.2% for the first six months of fiscal year 2018.

Total Operating Revenue

The combined total operating revenue increased \$95.8 million or 2.0% to \$4,909.4 million for the first six months of fiscal year 2019 compared to \$4,813.6 million for the first six months of fiscal year 2018.

Net patient care revenue, increased \$159.3 million or 3.8% to \$4,299.7 million for the first six months of fiscal year 2019 compared to \$4,140.4 million for the first six months of fiscal year 2018. The increase in net patient care revenue reflects higher volumes in other outpatient registrations, clinic visits, and patient encounters for fiscal year 2019.

Premium revenue decreased \$14.7 million or -3.6% to \$397.6 million for the first six months of fiscal year 2019 compared to \$412.3 million for the first six months of fiscal year 2018. Premium revenue decreased for the first six months of fiscal year 2019 due to a reduction in fully-insured group and individual membership year over year.

Net assets released from restrictions for operations increased \$1.0 million or 3.1% to \$33.0 million for the first six months of fiscal year 2019 compared to \$32.0 million for the first six months of fiscal year 2018.

Total Operating Expenses

Combined total operating expenses for the first six months of fiscal year 2019 were \$4,493.7 million, an increase of \$63.5 million or 1.4% compared to \$4,430.2 million for the first six months of fiscal year 2018.

Salaries, wages, and employee benefits expense increased \$31.6 million or 1.4% to \$2,253.8 million for the first six months of fiscal year 2019 compared to \$2,222.2 million for the first six months of fiscal year 2018, representing approximately 45.9% and 46.2% of total operating revenue for the first six months of fiscal years 2019 and 2018, respectively. Salaries, wages, and employee benefits expense represented approximately 50.2% of total operating expenses for the first six months of fiscal years 2019 and 2018.

Quarterly Disclosure Report for December 31, 2018

Supplies and other operating expenses increased \$17.2 million or 0.9% for the first six months of fiscal year 2019 to \$1,835.9 million compared to \$1,818.7 million for the first six months of fiscal year 2018, and represented approximately 37.4% and 37.8% of total operating revenue for the first six months of fiscal years 2019 and 2018, respectively. Supplies and other operating expenses represented approximately 40.9% and 41.1% of total operating expenses for the first six months of fiscal years 2019 and 2018, respectively.

Medical claims decreased \$4.4 million or -2.9% for the first six months of fiscal year 2019 to \$145.0 million compared to \$149.4 million for the first six months of fiscal year 2018. Medical claims decreased when compared to the first six months of fiscal year 2018 due to reductions in fully-insured group and individual membership.

Depreciation and amortization increased \$7.0 million or 3.7% to \$195.3 for the first six months of fiscal year 2019 compared to \$188.3 million for the first six months of fiscal year 2018.

Interest expense increased \$4.5 million or 7.5% to \$64.6 million for the first six months of fiscal year 2019 compared to \$60.1 million for the first six months of fiscal year 2018.

BSWH Operating Expenses (\$ Thousands)	Year Ended		Six Months Ended	
	June 30,		December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
Salaries, wages, and employee benefits	\$ 4,367,194	\$ 4,444,457	\$ 2,222,151	\$ 2,253,774
Supplies	1,582,408	1,595,620	806,004	845,585
Other operating expenses	1,893,278	2,014,958	1,012,681	990,309
Medical claims	357,860	291,107	149,376	144,972
Losses (gains) on fixed asset sales and disposals, net	2,649	(5,073)	(8,435)	(839)
Impairment losses	87,943	52,466	-	-
Depreciation and amortization	385,528	379,168	188,303	195,291
Interest expense	115,743	121,633	60,110	64,568
Total operating expenses	<u>\$ 8,792,603</u>	<u>\$ 8,894,336</u>	<u>\$ 4,430,190</u>	<u>\$ 4,493,660</u>

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

Full-Time Equivalents

Full-time equivalents (FTEs) are the number of total hours worked in a given period divided by the maximum number of compensable hours in a period as defined by law. The following table displays FTEs for employees of BSWH, which include physicians, advanced practice providers, and other employees.

BSWH Employees	Obligated Affiliates	SWHP	Other Entities	December 31, 2018 Total
Physician FTEs	1,150	-	958	2,108
Advanced practice provider FTEs	490	-	339	829
Joint venture FTEs ⁽¹⁾	-	-	5,670	5,670
Other employee FTEs	26,564	492	10,503	37,559
Total FTEs	28,204	492	17,470	46,166

⁽¹⁾ Joint venture FTEs above include THVG JV, BIR JV, BTDI JV, and EBD JV. ESWCT, LLC FTEs are not included in the table.

Nonoperating Gains (Losses)

The System recorded unrestricted unrealized losses on investments of \$186.8 million for the first six months of fiscal year 2019 compared to unrestricted unrealized gains on investments of \$111.8 million for the first six months of fiscal year 2018. Unrestricted investment income and realized gains on investments were \$65.0 million for the first six months of fiscal year 2019 compared to unrestricted investment income and realized gains on investments of \$73.5 million for the first six months of fiscal year 2018, representing a decrease of \$8.5 million or -11.6%. The System recorded unrealized losses in its interest rate swap portfolio of \$8.8 million for the first six months of fiscal year 2019 compared to unrealized gains of \$9.0 million for the first six months of fiscal year 2018 due to a decrease in interest rate fluctuations since June 30, 2018.


THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018


Utilization Statistics

BSWH derives its patient revenue from managed care companies, Medicare, Medicaid, commercial insurers, self paying patients, and other sources.

The following graph approximates the percentages of gross patient revenue by payor which includes intercompany activity related to the insured patients of the Health Plan.



Quarterly Disclosure Report for December 31, 2018



THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

	Year Ended		Six Months Ended	
	June 30,		December 31,	
	2017	2018	2017	2018
Licensed Beds	5,371	5,125	5,397	5,149
Inpatient Admissions ⁽¹⁾	235,112	233,237	120,057	111,155
Patient Days	1,127,959	1,111,454	548,582	520,402
Occupancy*	66.9%	60.8%	62.5%	63.4%
Average Length of Stay (Days)	4.8	4.8	4.6	4.7
Average Daily Census	3,090	3,045	2,981	2,828
Discharges	235,103	233,737	120,116	111,218
Emergency Room Visits	857,198	863,024	437,262	403,672
Inpatient Surgical Cases	65,310	64,895	33,460	31,549
Outpatient Surgical Cases	191,865	200,561	102,816	109,429
Outpatient Registrations	3,851,015	3,980,821	1,979,688	2,095,553
Clinic Visits (IP & OP)	3,072,119	3,255,645	1,573,449	1,676,059
Patient Encounters	3,603,664	3,761,762	1,840,623	1,936,761
Relative Value Units ⁽²⁾	15,563,238	16,391,475	7,985,422	8,338,643
Deliveries	31,781	31,253	16,624	15,519
Gross Outpatient Revenue as a Percent of Total Gross Patient Revenues	59.4%	61.6%	61.0%	63.1%

(1) Admissions include adult, pediatric, and special care nursery.

(2) Relative value units represent amounts for BSWH.

As statistical definitions are redefined and aligned related to the merger, prior quarter statistics may be updated accordingly for comparative purposes.

* The occupancy % for the prior periods has been restated for a previous error in staffed beds at BT East Dallas JV, a non-obligated affiliate.

	Year Ended		Six Months Ended	
	June 30,		December 31,	
	2017	2018	2017	2018
Licensed Beds	3,413	3,436	3,411	3,436
Inpatient Admissions ⁽¹⁾	156,579	160,158	80,377	79,590
Patient Days	786,564	776,928	386,515	382,552
Occupancy	73.1%	70.1%	70.1%	68.5%
Average Length of Stay (Days)	5.0	4.9	4.8	4.8
Average Daily Census	2,155	2,129	2,101	2,079
Discharges	156,669	160,125	80,120	79,486
Emergency Room Visits	452,124	471,193	232,231	237,449
Inpatient Surgical Cases	39,732	39,381	19,651	19,786
Outpatient Surgical Cases	63,913	66,197	33,398	33,481
Outpatient Registrations	2,837,938	2,935,096	1,449,099	1,548,086
Clinic Visits (IP & OP)	2,755,984	2,938,292	1,417,323	1,516,289
Relative Value Units ⁽²⁾	6,857,230	7,327,645	3,543,944	3,778,399
Deliveries	22,419	22,553	11,876	11,714
Gross Outpatient Revenue as a Percent of Total Gross Patient Revenues	53.8%	55.3%	55.1%	55.6%

(1) Admissions include adult, pediatric, and special care nursery.

(2) Relative value units represent amounts for BSWH.

As statistical definitions are redefined and aligned related to the merger, prior quarter statistics may be updated accordingly for comparative purposes.

Quarterly Disclosure Report for December 31, 2018

	Year Ended		Six Months Ended	
	June 30,		December 31,	
	2017	2018	2017	2018
Licensed Beds	1,958	1,689	1,986	1,713
Inpatient Admissions ⁽¹⁾	78,533	73,079	39,680	31,565
Patient Days	341,395	334,526	162,067	137,850
Occupancy*	56.0%	46.5%	49.9%	52.5%
Average Length of Stay (Days)	4.4	4.5	4.1	4.3
Average Daily Census	935	916	880	749
Discharges	78,434	73,612	39,996	31,732
Emergency Room Visits	405,074	391,831	205,031	166,223
Inpatient Surgical Cases	25,578	25,514	13,809	11,763
Outpatient Surgical Cases	127,952	134,364	69,418	75,948
Outpatient Registrations	1,013,077	1,045,725	530,589	547,467
Clinic Visits (IP & OP)	316,135	317,353	156,126	159,770
Patient Encounters	3,603,664	3,761,762	1,840,623	1,936,761
Relative Value Units ⁽²⁾	8,706,008	9,063,830	4,441,478	4,560,245
Deliveries	9,362	8,700	4,748	3,805
Gross Outpatient Revenue as a Percent of Total Gross Patient Revenues	66.7%	70.1%	68.6%	73.7%

(1) Admissions include adult, pediatric, and special care nursery.

(2) Relative value units represent amounts for BSWH.

As statistical definitions are redefined and aligned related to the merger, prior quarter statistics may be updated accordingly for comparative purposes.

* The occupancy % for the prior periods has been restated for a previous error in staffed beds at BT East Dallas JV, a non-obligated affiliate.

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

BSWH Adult and Pediatric Licensed Beds - December 31, 2018	
	Licensed Beds
Baylor University Medical Center	914
Baylor Scott & White Medical Center - Temple	576
Baylor Scott & White All Saints Medical Center - Fort Worth	538
Baylor Scott & White Medical Center - Grapevine	302
Baylor Scott & White Medical Center - Hillcrest	236
Baylor Scott & White Medical Center - Plano	160
Baylor Scott & White Medical Center - McKinney	143
Baylor Scott & White Medical Center - Waxahachie	129
Baylor Scott & White Medical Center - College Station	119
Baylor Scott & White Medical Center - Lakeway ⁽²⁾	106
Baylor Scott & White Medical Center - Round Rock	101
Baylor Scott & White McLane Children's Medical Center ⁽¹⁾	64
Baylor Scott & White Continuing Care Hospital	48
Obligated Affiliates Subtotal	3,436
Texas Health Ventures Group (10 hospitals)	309
Baylor Scott & White Medical Center - Irving	293
Baylor Scott & White Medical Center - Carrollton	216
BIR JV, LLP (4 hospitals)	214
Baylor Scott & White Medical Center - Centennial	118
The Heart Hospital Baylor Plano	114
Baylor Scott & White Medical Center - Lake Pointe	112
EBD JV, LLP (8 emergency medical centers)	64
Baylor Jack and Jane Hamilton Heart and Vascular Hospital	60
Baylor Scott & White Medical Center - Brenham	60
Baylor Scott & White Medical Center - Marble Falls	46
Baylor Scott & White Medical Center - Llano	27
Baylor Scott & White Medical Center - Pflugerville	25
Baylor Scott & White Medical Center - Taylor	25
The Heart Hospital Baylor Denton	22
ESWCT, LLC (1 emergency medical center)	8
Non-Obligated Alliliates Subtotal	1,713
Total	5,149
⁽¹⁾ Baylor Scott & White McLane Children's Medical Center is operated as part of Baylor Scott & White Medical Center - Temple.	
⁽²⁾ Baylor Scott & White Medical Center - Lakeway is operated as part of Baylor Scott & White Medical Center - Round Rock.	
Source: Texas Department of Health, January 4, 2019	

Quarterly Disclosure Report for December 31, 2018

Liquidity

Unrestricted cash and investments of \$4.8 billion at December 31, 2018 decreased \$176.5 million as compared to unrestricted cash and investments of \$5.0 billion at June 30, 2018 after capital expenditures of \$268.2 million and net losses on trading investments of \$121.2 million. Unrestricted days cash on hand decreased to 204.9 days at December 31, 2018 from 212.7 days at June 30, 2018. Including restricted funds, days cash on hand totaled 238.1 days at December 31, 2018 compared to 247.4 days at June 30, 2018. The debt to capitalization ratio is 38.0% at December 31, 2018 and June 30, 2018, respectively, and total assets are \$12.1 billion at December 31, 2018 and June 30, 2018.

BSWH Cash and Investments				
(\$ Thousands)				
	June 30,		December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
Cash and cash equivalents ⁽¹⁾	\$ 1,189,606	\$ 1,263,591	\$ 1,255,680	\$ 946,812
Short-term investments ⁽²⁾	192,269	179,540	184,102	193,662
Long-term investments ⁽³⁾	<u>3,886,786</u>	<u>4,327,713</u>	<u>4,126,955</u>	<u>4,421,287</u>
Total cash and investments	5,268,661	5,770,844	5,566,737	5,561,761
Less: restricted cash and investments ⁽⁴⁾	<u>795,601</u>	<u>808,631</u>	<u>847,285</u>	<u>776,084</u>
Total unrestricted cash and investments	<u>\$ 4,473,060</u>	<u>\$ 4,962,213</u>	<u>\$ 4,719,452</u>	<u>\$ 4,785,677</u>
Average daily operating expenses (less depreciation)	\$ 23,033	\$ 23,329	\$ 23,054	\$ 23,361
Unrestricted days cash on hand ⁽⁵⁾	194.2	212.7	204.7	204.9
Days cash on hand ⁽⁶⁾	228.7	247.4	241.5	238.1

(1) Cash and cash equivalents are composed of assets that may be immediately converted to cash.

(2) Short-term investments are assets that are convertible to cash in one year or less.

(3) Long-term investments are comprised of U.S. small, mid and large capitalization stocks, international stocks, intermediate term fixed income securities, hedge funds, real estate, and private equity.

(4) Restricted cash and investments is the sum of the restricted long-term investments, assets restricted by donors, assets held by bond trustees, and assets required to meet self-insurance obligations.

(5) Unrestricted days cash on hand is calculated as unrestricted cash and investments divided by average daily operating expenses (less depreciation).

(6) Days cash on hand includes restricted funds.

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health Self Liquidity Report (\$ Thousands)		December 31, 2018
Daily Liquidity		
Money Market Funds - Aaa-rated		\$ 25,758
Checking and deposit accounts at P-1 rated bank		354,822
Short-term investment funds at P-1 rated bank		14,580
Subtotal Daily Liquidity (Cash & Securities)		395,160
\$400 Million General Purpose LOC (undrawn amount) ⁽¹⁾		320,600
Subtotal Daily Liquidity		\$ 715,760
Weekly Liquidity		
Fixed Income: Publicly Traded Fixed Income Securities rated at least Aa3		635,225
Fixed Income: Publicly Traded Fixed Income Securities rated below Aa3		788,255
Equities: Exchange Traded Equity (ownership of shares of stock)		166,213
Equities: Equity Funds		616,676
Subtotal Weekly Liquidity		2,206,369
Total Daily and Weekly Liquidity		\$ 2,922,129
Longer Term Liquidity		
Funds, vehicles, investments that allow withdrawals with one month notice or longer		\$ 1,065,605
⁽¹⁾ Baylor Scott & White Holdings \$400MM line of credit expires January 14, 2020. The table above sets forth those assets that would reasonably be available to BSWH to satisfy a liquidity event. The table does not include assets held by affiliates of BSWH that would not be reasonably available to BSWH to satisfy a liquidity event, including assets held by the five foundations as described further in this report, THVG JV, Texas Heart Hospital of the Southwest, LLP and Baylor Heart and Vascular Center, LLP, among others.		

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

NET ASSETS OF THE FOUNDATIONS

The System operates five philanthropic foundations which include Baylor Health Care System Foundation, Scott & White Healthcare Foundation, All Saints Health Foundation, Irving Healthcare Foundation, and Scott & White Healthcare Foundation Brenham. The cumulative net assets of these five entities are as follows:

Net Assets of the Foundations (\$ Thousands)	June 30,		December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
	Unrestricted	\$ 147,835	\$ 158,745	\$ 149,345
Temporarily restricted	269,586	291,725	288,387	277,004
Permanently restricted	260,812	273,983	273,236	276,925
Total	<u>\$ 678,233</u>	<u>\$ 724,453</u>	<u>\$ 710,968</u>	<u>\$ 696,486</u>

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health				
Combined Balance Sheets				
(\$ Thousands)				
	June 30,		December 31,	
ASSETS	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
CURRENT ASSETS:				
Cash and cash equivalents	\$ 1,189,606	\$ 1,263,591	\$ 1,255,680	\$ 946,812
Short-term investments	192,269	179,540	184,102	193,662
THVG funds due from United Surgical Partners, Inc.	85,888	117,752	98,938	117,029
Accounts receivables:				
Patient, net	816,598	804,751	880,785	865,998
Premium	116,182	92,556	79,040	86,606
Other	185,862	187,159	242,864	182,464
Other current assets	254,466	347,551	300,447	420,536
Total current assets	<u>2,840,871</u>	<u>2,992,900</u>	<u>3,041,856</u>	<u>2,813,107</u>
LONG-TERM INVESTMENTS:				
Unrestricted	3,091,185	3,519,082	3,279,670	3,645,203
Restricted	471,075	505,634	506,303	488,836
Total long-term investments	<u>3,562,260</u>	<u>4,024,716</u>	<u>3,785,973</u>	<u>4,134,039</u>
ASSETS WHOSE USE IS LIMITED:				
Other designated assets	165,128	162,361	175,719	145,508
Self insurance reserves	98,272	110,783	114,255	123,530
Funds held by bond trustee	61,126	29,853	51,008	18,210
Total assets whose use is limited	<u>324,526</u>	<u>302,997</u>	<u>340,982</u>	<u>287,248</u>
ASSETS HELD FOR SALE	16,354	-	16,324	-
PROPERTY AND EQUIPMENT, net	3,525,384	3,683,590	3,577,277	3,768,179
CONTRIBUTIONS RECEIVABLE, net	61,014	185,946	176,951	178,505
INTEREST IN NET ASSETS OF RELATED FOUNDATION	4,048	4,217	4,220	4,217
OTHER LONG-TERM ASSETS:				
Equity investment in unconsolidated entities	57,548	61,748	64,243	61,653
Goodwill and intangible assets, net	734,291	864,239	848,433	878,467
Other	20,310	17,708	20,410	14,927
Total other long-term assets	<u>812,149</u>	<u>943,695</u>	<u>933,086</u>	<u>955,047</u>
Total assets	<u>\$ 11,146,606</u>	<u>\$ 12,138,061</u>	<u>\$ 11,876,669</u>	<u>\$ 12,140,342</u>

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health				
Combined Balance Sheets - continued				
(\$ Thousands)				
	June 30,		December 31,	
LIABILITIES AND NET ASSETS	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
CURRENT LIABILITIES:				
Current maturities of long-term debt and capital lease obligations	\$ 126,644	\$ 131,040	\$ 52,754	\$ 62,302
Long-term debt subject to short-term remarketing arrangements	95,000	95,000	95,000	95,000
Commercial paper	-	187,868	187,967	207,438
Trade accounts payable	303,893	338,506	294,075	331,231
Accrued liabilities:				
Payroll related	373,398	410,212	354,460	354,307
Third-party programs	87,195	113,845	88,449	80,951
Medical claims payable	37,354	28,878	32,788	27,379
Other	398,896	492,065	467,655	481,999
Total current liabilities	<u>1,422,380</u>	<u>1,797,414</u>	<u>1,573,148</u>	<u>1,640,607</u>
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS,				
less current maturities	3,171,837	3,087,064	3,062,642	3,121,040
OTHER LONG-TERM LIABILITIES:				
Self insurance and other insurance liabilities	99,208	107,627	113,993	122,075
Interest rate swap liabilities, net	265,129	220,123	260,883	228,455
Other	305,964	307,391	299,686	305,744
Total other long-term liabilities	<u>670,301</u>	<u>635,141</u>	<u>674,562</u>	<u>656,274</u>
Total liabilities	<u>5,264,518</u>	<u>5,519,619</u>	<u>5,310,352</u>	<u>5,417,921</u>
COMMITMENTS AND CONTINGENCIES				
NONCONTROLLING INTERESTS - REDEEMABLE	443,128	424,704	510,049	449,577
NET ASSETS:				
Unrestricted - attributable to BSWH	4,695,399	5,212,273	5,093,091	5,298,991
Unrestricted - noncontrolling interests - nonredeemable	202,603	281,773	267,123	294,772
Total unrestricted net assets	<u>4,898,002</u>	<u>5,494,046</u>	<u>5,360,214</u>	<u>5,593,763</u>
Temporarily restricted	276,585	422,107	419,197	398,633
Permanently restricted	264,373	277,585	276,857	280,448
Total net assets	<u>5,438,960</u>	<u>6,193,738</u>	<u>6,056,268</u>	<u>6,272,844</u>
Total liabilities and net assets	<u>\$ 11,146,606</u>	<u>\$ 12,138,061</u>	<u>\$ 11,876,669</u>	<u>\$ 12,140,342</u>

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health				
Combined Statements of Operations and Change in Net Assets				
(\$ Thousands)				
	Year Ended June 30,		Six Months Ended December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
OPERATING REVENUE:				
Net patient care revenue	\$ 8,664,811	\$ 8,902,330	\$ 4,532,159	\$ 4,299,729
Less patient related bad debt expense*	927,168	744,220	391,763	-
Net patient care revenue, net of patient related bad debt expense	<u>7,737,643</u>	<u>8,158,110</u>	<u>4,140,396</u>	<u>4,299,729</u>
Premium revenue	903,261	827,199	412,282	397,618
Other operating revenue	378,332	424,107	228,843	179,033
Net assets released from restrictions for operations	65,240	67,208	32,041	33,037
Total operating revenue	<u>9,084,476</u>	<u>9,476,624</u>	<u>4,813,562</u>	<u>4,909,417</u>
OPERATING EXPENSES:				
Salaries, wages, and employee benefits	4,367,194	4,444,457	2,222,151	2,253,774
Supplies	1,582,408	1,595,620	806,004	845,585
Other operating expenses	1,893,278	2,014,958	1,012,681	990,309
Medical claims	357,860	291,107	149,376	144,972
Losses (gains) on fixed asset sales and disposals, net	2,649	(5,073)	(8,435)	(839)
Impairment losses	87,943	52,466	-	-
Depreciation and amortization	385,528	379,168	188,303	195,291
Interest	115,743	121,633	60,110	64,568
Total operating expenses	<u>8,792,603</u>	<u>8,894,336</u>	<u>4,430,190</u>	<u>4,493,660</u>
Income from operations	<u>291,873</u>	<u>582,288</u>	<u>383,372</u>	<u>415,757</u>
NONOPERATING GAINS (LOSSES):				
Gains (losses) on investments, net	271,331	216,490	187,554	(121,242)
Interest rate swap activity	82,624	31,033	(2,962)	(18,213)
Contributions	779	30	99	1
Equity in (losses) gains of unconsolidated entities	(9,515)	36,919	36,805	141
Loss from extinguishment of debt	-	(721)	(721)	(200)
Other	378	331	272	69
Total nonoperating gains (losses)	<u>345,597</u>	<u>284,082</u>	<u>221,047</u>	<u>(139,444)</u>
REVENUE AND GAINS IN EXCESS OF EXPENSES AND LOSSES BEFORE TAXES	<u>637,470</u>	<u>866,370</u>	<u>604,419</u>	<u>276,313</u>
LESS INCOME TAX EXPENSE	<u>7,015</u>	<u>25,311</u>	<u>8,923</u>	<u>8,649</u>
REVENUE AND GAINS IN EXCESS OF EXPENSES AND LOSSES	<u>630,455</u>	<u>841,059</u>	<u>595,496</u>	<u>267,664</u>
*As of FY2019, BSWH adopted the provisions of ASU 2014-09.				

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health				
Combined Statements of Operations and Changes in Net Assets - continued				
(\$ Thousands)				
	Year Ended June 30,		Six Months Ended December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
OTHER CHANGES IN UNRESTRICTED NET ASSETS:				
Unrealized losses on investments, net	\$ (1,786)	\$ (2,688)	\$ (2,344)	\$ (575)
Net assets released from restrictions for capital expenditures	25,584	12,471	3,972	16,488
Other changes in net assets attributable to noncontrolling interests - nonredeemable	(65,871)	(6,781)	9,146	(37,411)
Revenue and gains in excess of expenses and losses attributable to noncontrolling interests - redeemable	(206,727)	(255,035)	(143,748)	(150,727)
Net assets acquired	185	-	-	6,955
Other	9,306	7,018	(310)	(2,677)
	<u>391,146</u>	<u>596,044</u>	<u>462,212</u>	<u>99,717</u>
INCREASE IN UNRESTRICTED NET ASSETS				
CHANGES IN TEMPORARILY RESTRICTED NET ASSETS:				
Contributions	69,369	193,302	152,385	37,865
Realized gains and investment income, net	17,369	23,555	13,467	13,671
Unrealized gains (losses) on investments, net	18,562	10,042	12,797	(25,131)
Changes in value of split-interest agreements	386	(546)	297	(585)
Net assets released from restrictions for operations	(65,240)	(67,208)	(32,041)	(33,037)
Net assets released from restrictions for capital expenditures	(25,584)	(12,471)	(3,972)	(16,488)
Changes in net assets of related foundation	281	138	170	-
Other	121	(1,290)	(491)	231
	<u>15,264</u>	<u>145,522</u>	<u>142,612</u>	<u>(23,474)</u>
INCREASE (DECREASE) IN TEMPORARILY RESTRICTED NET ASSETS				
CHANGES IN PERMANENTLY RESTRICTED NET ASSETS:				
Contributions	918	12,134	11,459	3,441
Realized gains and investment income, net	175	2,333	542	699
Unrealized gains (losses) on investments, net	370	(122)	(83)	(651)
Changes in value of split-interest agreements	918	(1,763)	224	(440)
Changes in net assets of related foundation	27	31	2	-
Other	111	599	340	(186)
	<u>2,519</u>	<u>13,212</u>	<u>12,484</u>	<u>2,863</u>
INCREASE IN PERMANENTLY RESTRICTED NET ASSETS				
INCREASE IN NET ASSETS				
	408,929	754,778	617,308	79,106
NET ASSETS, beginning of period	<u>5,030,031</u>	<u>5,438,960</u>	<u>5,438,960</u>	<u>6,193,738</u>
NET ASSETS, end of period	<u>\$ 5,438,960</u>	<u>\$ 6,193,738</u>	<u>\$ 6,056,268</u>	<u>\$ 6,272,844</u>

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health				
Combined Statements of Cash Flows				
(\$ Thousands)				
	June 30,		December 31,	
	<u>2017</u>	<u>2018</u>	<u>2017</u>	<u>2018</u>
Cash Flows From Operating Activities:				
Increase in net assets	\$ 408,929	\$ 754,778	\$ 617,308	\$ 79,106
Adjustments to reconcile increase in net assets to net cash provided by operating activities:				
Loss from extinguishment of debt	-	721	721	200
Unrealized (gains) losses on investments, net	(155,813)	(77,537)	(124,471)	212,580
Realized gains on investments, net	(105,222)	(107,034)	(54,149)	(38,958)
Unrealized (gains) losses on interest rate swap, net	(111,307)	(53,466)	(8,956)	8,752
Contributions restricted for long-term purposes	(918)	(12,134)	(11,459)	(3,441)
Patient related bad debt expense	927,168	744,220	391,763	-
Depreciation and amortization	385,528	379,168	188,303	195,291
Impairment losses	87,943	52,466	-	-
Losses (gains) on fixed asset sales and disposals, net	2,649	(5,073)	(8,435)	(839)
Equity in losses (earnings) of unconsolidated entities	9,515	(36,919)	(36,805)	(141)
Change in value of split-interest agreements	(1,304)	2,309	(521)	1,025
Deferred rent	3,444	(3,528)	(790)	(182)
Other changes attributable to noncontrolling interests	272,598	271,358	134,602	188,138
Net assets acquired	(185)	-	-	(6,955)
Changes in operating assets and liabilities (net of acquisitions):				
Increase in net patient accounts receivable	(956,746)	(735,554)	(441,153)	(61,247)
(Increase) decrease in other accounts receivable	(43,212)	26,176	(19,835)	11,216
Increase in other assets	(35,497)	(185,372)	(132,662)	(66,255)
Increase (decrease) in trade accounts payable and accrued liabilities	8,786	154,349	27,205	(108,041)
Increase in other long-term liabilities	53,833	35,776	21,747	22,105
Net cash provided by operating activities	<u>750,189</u>	<u>1,204,704</u>	<u>542,413</u>	<u>432,354</u>
Cash Flows From Investing Activities:				
Purchases of property and equipment, net	(406,207)	(485,271)	(218,553)	(268,233)
Cash proceeds from sales of assets	3,088	34,332	9,782	1,352
Cash paid for acquisitions, net of cash received	(83,875)	(48,949)	(42,317)	(9,248)
(Increase) decrease in THVG funds due from United Surgical Partners, Inc.	(15,624)	(31,864)	(13,050)	723
Increase in trading investments	(226,306)	(272,696)	(33,225)	(289,742)
Net payments on interest rate swaps	(6,352)	(13,869)	(7,259)	(9,977)
Decrease (increase) in other than trading investments	7,279	(1,528)	(2,961)	(9,383)
(Increase) decrease in assets whose use is limited	(48,556)	21,529	(16,456)	15,749
Net cash used in investing activities	<u>(776,553)</u>	<u>(798,316)</u>	<u>(324,039)</u>	<u>(568,759)</u>
Cash Flows From Financing Activities:				
Principal payments on long-term debt	(75,424)	(515,732)	(421,468)	(53,958)
Proceeds from issuance of long-term debt	75,443	553,178	416,655	37,808
Distributions to noncontrolling interests	(320,346)	(442,558)	(165,944)	(162,126)
Purchases of noncontrolling interests	(18,565)	(34,727)	(19,805)	(9,189)
Sales of noncontrolling interests	25,956	96,165	26,730	4,940
Cash receipts restricted for long-term purposes	2,045	12,110	11,968	2,568
Annuity payments to beneficiaries	(888)	(839)	(436)	(417)
Net cash used in financing activities	<u>(311,779)</u>	<u>(332,403)</u>	<u>(152,300)</u>	<u>(180,374)</u>
Net (Decrease) Increase in Cash and Cash Equivalents	(338,143)	73,985	66,074	(316,779)
Cash and Cash Equivalents, beginning of period	<u>1,527,749</u>	<u>1,189,606</u>	<u>1,189,606</u>	<u>1,263,591</u>
Cash and Cash Equivalents, end of period	<u>\$ 1,189,606</u>	<u>\$ 1,263,591</u>	<u>\$ 1,255,680</u>	<u>\$ 946,812</u>

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements

1. ORGANIZATION

Baylor Scott & White Holdings (BSW Holdings), a Texas nonprofit corporation exempt from federal income taxation under Section 501(c)(3) of the Internal Revenue Code, and its controlled affiliates (collectively, the “System”) were created from the combination of two Texas healthcare systems, Baylor Health Care System (BHCS) and its affiliates, and Scott & White Healthcare (SWH) and its affiliates. BSW Holdings and Baylor Scott & White Health (BSW Health), a Texas nonprofit corporation, were created by BHCS and SWH in connection with their combination. BSW Holdings is the sole member of BHCS, SWH, and BSW Health and has control and substantial reserved powers over all BHCS and SWH material affiliates. BHCS and its material affiliates are collectively referred to as “Baylor”. SWH and its material affiliates are collectively referred to as “Scott & White”. BSW Holdings and its controlled affiliates are collectively referred to as the “System” or “BSWH”.

The combined financial statements include the accounts of BSW Holdings, BSW Health, BHCS, SWH, Baylor University Medical Center (BUMC), Scott & White Memorial Hospital (SWMH), Scott & White Health Plan (the “Health Plan” or “SWHP”), five foundations, twenty-two community and specialty hospitals located throughout the Dallas and Fort Worth metroplex and the central Texas area, one wholly owned insurance subsidiary, Baylor Quality Health Care Alliance, LLC, an accountable care organization, four physician practice organizations (HealthTexas Provider Network, Scott & White Clinic, Hillcrest Family Health Center, and Hillcrest Physician Services), and other related entities. Investments in certain related entities with 50.0% or less ownership are accounted for using the equity method. The transactions and balances for investments in certain related entities with greater than 50.0% ownership, or where the System exercises board control, are included in the accompanying combined financial statements with related noncontrolling interests reported in the combined financial statements. These entities include five acute and specialty hospitals referenced above, along with partnerships in: Texas Health Ventures Group, LLC (THVG), providing short stay hospital and outpatient surgery services, BIR JV, LLP, providing rehabilitation services, BTDI JV, LLP, providing imaging services, EBD JV, LLP and ESWCT, LLC, providing emergency medical services, HTPN Gastroenterology Services, LLP, providing endoscopic services, and THVG Bariatric, LLC, which has provided bariatric services. All significant intercompany accounts and transactions among entities included in the combined financial statements have been eliminated.

The following summarizes significant changes in the System in 2017 - 2019:

THVG

BUMC has a majority ownership of 50.1% in THVG with USP North Texas, Inc. (USP), a Texas corporation and subsidiary of United Surgical Partners, Inc. (USPI) holding the

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

remaining 49.9%. THVG had net patient care revenue included in the System's combined financial statements of approximately \$645,911,000 and \$566,252,000 in the first six months of fiscal years 2019 and 2018, respectively.

THVG completed the acquisition of one outpatient center in fiscal year 2017. THVG recorded goodwill and intangible assets, net, of approximately, \$19,852,000, fixed assets of approximately \$517,000, noncontrolling interests of approximately \$16,674,000, and other net liabilities of approximately \$3,695,000 in 2017.

THVG completed the acquisition of one surgical hospital in fiscal year 2018. THVG recorded goodwill and intangible assets, net, of approximately \$111,874,000, fixed assets of approximately \$18,276,000, noncontrolling interests of approximately \$91,338,000, and other net liabilities of approximately \$38,812,000 in 2018.

BT East Dallas JV, LLP and BT Garland JV, LLP

Effective January 1, 2016, two Texas limited liability partnerships were formed between the System and Healthcare Network Texas, Inc., a Delaware corporation and subsidiary of Tenet Healthcare Corporation (Tenet). BUMC has a majority ownership of 75% of BT East Dallas JV, LLP, (BT East Dallas) with Tenet holding the remaining 25%. Baylor Medical Centers at Garland and McKinney (Garland), a Texas nonprofit corporation wholly owned by BHCS, has a majority ownership of 50.1% of BT Garland JV, LLP (Garland JV) with Tenet holding the remaining 49.9%. The purpose of these partnerships was to own, operate, and manage five community hospitals focused on delivering integrated, value-based care to communities in Rockwall, Collin, and Dallas counties.

Effective June 9, 2017, BSW Holdings approved the proposed divestiture of Baylor Scott & White Medical Center – Garland (BSWMC – Garland) and Baylor Scott & White Medical Center – White Rock (White Rock), a hospital operated by BT East Dallas JV, LLP, and classification as assets held for sale. Due to the proposed divestiture and their classification as held for sale, an impairment assessment was required for the long-lived assets of BSWMC – Garland and White Rock under the assets to be disposed of by sale model. The assessment resulted in an adjustment for impairment of approximately \$70,624,000, recorded in the accompanying combined statements of operations for the year ended June 30, 2017. The remaining book value of BSWMC – Garland and White Rock is reported in assets held for sale in the accompanying combined balance sheets, as of June 30, 2017. After impairments, the remaining net book value of land, building and improvements, and major movable equipment and other was approximately \$3,900,000, \$5,427,000, and \$7,027,000, respectively, as of June 30, 2017.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

On December 14, 2017, BSWH announced that a decision was made to close BSWMC – Garland, a 113 bed hospital. The last day of operations was February 28, 2018. On December 22, 2017, BSWH and Tenet signed a definitive agreement for the sale of White Rock to Pipeline Health, a California-based hospital management company. The sale was completed on March 1, 2018.

On December 31, 2017, BSWH and Tenet signed a definitive agreement to restructure ownership of the three remaining hospitals: Baylor Scott & White Medical Center – Centennial, Baylor Scott & White Medical Center – Lake Pointe, and Baylor Scott & White Medical Center – Sunnyvale. BSWH and Tenet have owned the three hospitals through the BT East Dallas partnership since January 2016. Under the definitive agreement, BSWH acquired Tenet's interest in Baylor Scott & White Medical Center – Centennial and Baylor Scott & White Medical Center – Lake Pointe, and took over as manager and operator effective March 1, 2018. Baylor Scott & White Medical Center – Sunnyvale became part of the existing THVG joint venture between Tenet's subsidiary USPI and BSWH effective March 1, 2018. BSWH continues to be majority owner in the facility, while USPI took over its operation.

Lakeway

In September 2016, the System purchased Lakeway Regional Medical Center, a 106 bed multispecialty hospital now called Baylor Scott & White Medical Center - Lakeway, operated as a part of Scott & White Hospital - Round Rock.

Sale of Equity Method Investment

In July 2017, BSWH sold its equity investment in Med Fusion and ClearPoint Diagnostic Labs to Quest Diagnostics. The gain on sale of approximately \$37,322,000 is included in equity in earnings (losses) of unconsolidated entities in the accompanying combined statements of operations and changes in net assets.

Irving Hospital Authority Contribution to Irving

In August and November of 2017, Baylor Medical Center at Irving (Irving) executed lease amendments in which the Irving Hospital Authority (Authority) agreed to renovate, equip, and expand the properties leased from the Authority. The projects include renovation of portions of the existing hospital building, replacement of an existing central utility plant, construction of a new six-story tower, and the purchase of related furnishings and medical equipment. The projects will be completed in phases, with estimated completion of the entire project in mid 2020. Accordingly, in 2018 Irving recorded a temporarily restricted contribution of approximately \$122,700,000, net of discount, for building renovations, furnishings, and medical equipment, and a receipt of a right to use the new tower and central utility plant for the

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

remainder of the lease term under the existing lease agreement. The contribution receivable is reflected in the accompanying combined balance sheets and the temporarily restricted contribution is reflected in the changes in temporarily restricted net assets in the accompanying combined statements of operations and changes in net assets.

BIR JV, LLP

BIR JV, LLP completed the acquisition of one rehabilitation hospital in 2018. BIR JV, LLP recorded goodwill and intangible assets, net, of approximately \$6,493,000, fixed assets of approximately \$368,000, and other net liabilities of approximately \$6,861,000 in 2018.

Debt Restructuring

In November 2018, BSWH issued an additional \$20,000,000 of commercial paper under its \$400,000,000 commercial paper program. The proceeds were used to redeem the remaining \$19,700,000 of Baylor Health Care System Taxable Notes, Series 2000, with a loss on extinguishment of debt of \$200,000.

In December 2018, BSWH extended the \$400,000,000 revolving line of credit, which was scheduled to expire in January 2019, to January 2020.

2. SIGNIFICANT ACCOUNTING POLICIES

The accompanying combined financial statements of the System have been prepared in conformity with accounting principles generally accepted in the United States. The following is a summary of the significant accounting and reporting policies used in preparing the financial statements.

Adoption of New Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-15, “*Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.*” This ASU amendment requires management to assess an entity’s ability to continue as a going concern. Management should evaluate whether conditions or events, considered in the aggregate, exist that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The System applied the provisions of ASU 2014-15 in fiscal year 2017, which did not have a material impact on the combined financial statements.

In January 2015, FASB issued ASU 2015-01, “*Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.*” The amendments in ASU 2015-01 eliminate

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

the concept of extraordinary items in financial statements. The System applied the provisions of ASU 2015-01 in fiscal year 2017, which did not have a material impact on the combined financial statements.

In February 2015, FASB issued ASU 2015-02, “*Consolidation: Amendments to the Consolidation Analysis.*” The amendments in ASU 2015-02 improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The System applied the provisions of ASU 2015-02 in fiscal year 2018, which did not have a material impact on the combined financial statements.

In April 2015, FASB issued ASU 2015-03, “*Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs.*” The amendments in ASU 2015-03 are intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, consistent with debt discounts. The System applied the provisions of ASU 2015-03 in fiscal year 2017, which had no net impact on its financial position, results of operations, or cash flows.

In April 2015, FASB issued ASU 2015-05, “*Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement.*” The amendments in ASU 2015-05 provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The System applied the provisions of ASU 2015-05 in fiscal year 2017, which did not have a material impact on the combined financial statements.

In May 2015, FASB issued ASU 2015-07, “*Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent).*” This ASU removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. The System applied the provisions of ASU 2015-07 in fiscal year 2018, which did not have a material impact on the combined financial statements.

In May 2015, FASB issued ASU 2015-09, “*Disclosures about Short-Duration Contracts.*” This ASU requires insurance entities to disclose, for annual reporting periods, information

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

about the liability for unpaid claims and claim adjustment expenses. The amendments also require insurance entities to disclose information about significant changes in methodologies and assumptions used to calculate the liability for unpaid claims and claim adjustment expenses, including reasons for the change, and the effects on the financial statements. In addition, the amendments require insurance entities to disclose, for annual and interim reporting periods, a roll-forward of the liability for unpaid claims and claim adjustment expenses. For health insurance claims, the amendments require the disclosure of the total of incurred-but-not-reported liabilities, and expected development on reported claims included in the liability for unpaid claims and claim adjustment expenses. The System applied the provisions of ASU 2015-09 in fiscal year 2018, which did not have a material impact on the combined financial statements.

In July 2015, FASB issued ASU 2015-11, *“Simplifying the Measurement of Inventory.”* This ASU requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using last-in, first-out (LIFO) or the retail inventory method. The amendments do not apply to inventory that is measured using LIFO or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The System applied the provisions of ASU 2015-11 in fiscal year 2018, which did not have a material impact on the combined financial statements.

In August 2015, FASB issued ASU 2015-15, *“Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting).”* This ASU requires an entity to defer and present debt issuance costs as an asset and subsequently amortize the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The System applied the provisions of ASU 2015-15 in fiscal year 2017, which did not have a material impact on the combined financial statements.

In September 2015, FASB issued ASU 2015-16, *“Simplifying the Accounting for Measurement-Period Adjustments.”* This ASU requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period and any related income effects in the reporting period in which the adjustment amounts are determined. The ASU also requires an entity to present separately on the face of the income statement, or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The System applied the provisions of ASU 2015-16 in fiscal year 2018, which did not have a material impact on the combined financial statements.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

In March 2016, FASB issued ASU 2016-07, “*Simplifying the Transition to the Equity Method of Accounting.*” This ASU eliminates the requirement that when an investment qualifies for use of the equity method, as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments require that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. Retroactive adjustment of the investment is no longer required. The System applied the provisions of ASU 2016-07 in fiscal year 2018, which did not have a material impact on the combined financial statements.

In January 2017, FASB issued ASU 2017-02, “*Clarifying When a Not-for-Profit Entity That Is a General Partner or a Limited Partner Should Consolidate a For-Profit Limited Partnership or Similar Entity.*” This ASU retains the consolidation guidance that was in Subtopic 810-20. Not-for-profits that are general partners should continue to be presumed to control a for-profit limited partnership, regardless of the extent of their ownership interest, unless that presumption is overcome. The System applied the provisions of ASU 2017-02 in fiscal year 2018, which did not have a material impact on the combined financial statements.

In May 2014, August 2015, April 2016, May 2016, December 2016, and February 2017, FASB issued ASU 2014-09, “*Revenue from Contracts with Customers (Topic 606)*”; ASU 2015-14, “*Revenue from Contracts with Customers*”; ASU 2016-10, “*Identifying Performance Obligations and Licensing*”; ASU 2016-12, “*Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients*”; ASU 2016-20, “*Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers*”; and ASU 2017-05, “*Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets*”, respectively, which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) 605, “*Revenue Recognition.*” These ASU’s address when an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. These ASU’s are effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years for public business entities and not-for-profit entities that have issued publicly traded debt, and December 15, 2018 for all other entities as amended by ASU 2015-14. The System adopted the guidance under these ASU’s in fiscal year 2019 using a modified retrospective method of transition. While the adoption had an effect on the presentation of net patient care revenue, it did not have a material impact on the combined financial statements.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

Other Accounting Pronouncements

In November 2015, FASB issued ASU 2015-17, “*Balance Sheet Classification of Deferred Taxes*.” This ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The provisions of ASU 2015-17 are effective for fiscal years beginning after December 15, 2016, and interim periods within those years for public business entities, and December 15, 2017, and interim periods thereafter for all other entities. This ASU is not expected to have a material impact on the combined financial statements.

In January 2016, FASB issued ASU 2016-01, “*Recognition and Measurement of Financial Assets and Financial Liabilities*.” This ASU requires equity investments to be measured at fair value with changes in fair value recognized in net income. This ASU also requires the use of the exit price notion when measuring the fair value of financial instruments for disclosure purposes. A reporting organization must present separately, in other comprehensive income, the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk. The provisions of ASU 2016-01 are effective for fiscal years beginning after December 15, 2017, and interim periods within those years for public business entities, and December 15, 2018 for all other entities. The System is currently evaluating the impact of this ASU.

In February 2016, January 2018, July 2018, July 2018, and December 2018, FASB issued ASU 2016-02, “*Leases*”; ASU 2018-01, “*Land Easement Practical Expedient*”; ASU 2018-10, “*Codification Improvements to Topic 842, Leases*”; ASU 2018-11, “*Leases (Topic 842): Targeted Improvements*.”; and ASU 2018-20, “*Leases (Topic 842): Narrow-Scope Improvements for Lessors*”, respectively. These ASU’s require lessees to record a lease liability that represents the lessee’s future lease obligation payments and a right-of-use asset that represents the lessee’s right to use or control of a specified asset for the lease term. The main difference with current practice being that lessees will be required to record an asset and liability for what is now considered an operating lease. These ASU’s are effective for fiscal years beginning after December 15, 2018, and interim periods within those years for public business entities and not-for-profit entities that have issued publicly traded debt, and December 15, 2019 for all other entities. The System is currently evaluating the impact of these ASU’s and believes they will have a material impact on the combined financial statements.

In March 2016, FASB issued ASU 2016-05, “*Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships*.” This ASU clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

accounting criteria remain intact. The provisions of ASU 2016-05 are effective for fiscal years beginning after December 15, 2016, and interim periods within those years for public business entities, and December 15, 2017, and interim periods thereafter for all other entities. The System is currently evaluating the impact of this ASU.

In March 2016, FASB issued ASU 2016-06, “*Contingent Put and Call Options in Debt Instruments.*” This ASU clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts, which is one of the criteria for bifurcating an embedded derivative. Consequently, when a call (put) option is contingently exercisable, an entity does not have to assess whether the event that triggers the ability to exercise a call (put) option is related to interest rates or credit risks. The provisions of ASU 2016-06 are effective for fiscal years beginning after December 15, 2016, and interim periods within those years for public business entities, and December 15, 2017, and interim periods thereafter for all other entities. This ASU is not expected to have a material impact on the combined financial statements.

In June 2016 and November 2018, FASB issued ASU 2016-13, “*Financial Instruments-Credit Losses (Topic 326)*”, and, ASU 2018-19, “*Codification Improvements to Topic 326, Financial Instruments - Credit Losses*”, respectively. These ASU’s require health care entities to evaluate the collectability of the transaction price for goods or services that will be transferred to the patient rather than the stated contract price or the amount billed for those items. Additionally, health care entities are required to estimate variable consideration using either the “expected value” method or the “most-likely-amount” method. These amendments expand disclosures regarding revenue from contracts with customers. These ASU’s are effective for fiscal years beginning after December 15, 2020 and interim periods thereafter. The System is currently evaluating the impact of this ASU.

In August 2016, FASB issued ASU 2016-14, “*Presentation of Financial Statements of Not-for-Profit Entities.*” This ASU requires not-for-profit entities to report two classes of net assets, as well as enhances disclosures on board designated funds, liquidity, and functional expenses. The provisions of ASU 2016-14 are effective for fiscal years beginning after December 15, 2017, and interim periods thereafter. This ASU is not expected to have a material impact on the combined financial statements.

In August 2016, FASB issued ASU 2016-15, “*Classification of Certain Cash Receipts and Cash Payments.*” This ASU provides cash flow statement classification guidance related to debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, distributions made from equity method investees, separately identifiable cash flows, and application of the predominance

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

principle. The provisions of ASU 2016-15 are effective for fiscal years beginning after December 15, 2017, and interim periods within those years for public business entities, and December 15, 2018, and interim periods thereafter for all other entities. The System is currently evaluating the impact of this ASU.

In October 2016, FASB issued ASU 2016-16, *“Intra-Entity Transfers of Assets Other Than Inventory.”* This ASU requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The provisions of ASU 2016-16 are effective for fiscal years beginning after December 15, 2017, and interim periods within those years for public business entities, and December 15, 2018, and interim periods thereafter for all other entities. The System is currently evaluating the impact of this ASU.

In November 2016, FASB issued ASU 2016-18, *“Restricted Cash: a Consensus of the FASB Emerging Issues Task Force.”* This ASU requires a statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The provisions of ASU 2016-18 are effective for fiscal years beginning after December 15, 2017, and interim periods within those years for public business entities, and December 15, 2018, and interim periods thereafter for all other entities. This ASU is expected to have a material impact on the combined statements of cash flows.

In January 2017, FASB issued ASU 2017-01, *“Clarifying the Definition of a Business.”* By clarifying the definition of a business, the amendments of this ASU affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The provisions of ASU 2017-01 are effective for fiscal years beginning after December 15, 2017, and interim periods within those years for public business entities, and December 15, 2018, and interim periods within those years for all other entities. The System is currently evaluating the impact of this ASU.

In January 2017, FASB issued ASU 2017-04, *“Simplifying the Test for Goodwill Impairment.”* This ASU eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. The provisions of ASU 2017-04 are effective for fiscal years beginning after December 15, 2019, and interim periods within those years for public business entities, and December 15, 2021, and interim periods within those years for all other entities. The System is currently evaluating the impact of this ASU.

In March 2017, FASB issued ASU 2017-07, *“Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.”* This ASU requires that an employer report the service cost component in the same line item as other compensation costs

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The provisions of ASU 2017-07 are effective for fiscal years beginning after December 15, 2017, and interim periods within those years for public business entities, and December 15, 2018, and interim periods thereafter for all other entities. This ASU is not expected to have a material impact on the combined financial statements.

In March 2017, FASB issued ASU 2017-08, “*Premium Amortization on Purchased Callable Debt Securities*.” This ASU shortens the amortization period for certain callable debt securities held at a premium and requires the premium to be amortized to the earliest call date. However, the amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The provisions of ASU 2017-08 are effective for fiscal years beginning after December 15, 2018, and interim periods within those years for public business entities, and December 15, 2019, and interim periods thereafter for all other entities. The System is currently evaluating the impact of this ASU.

In June 2018, FASB issued ASU 2018-08, “*Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*.” These amendments clarify the accounting guidance around contributions of cash and other assets made and received by not-for-profit organizations and business enterprises. When the entity is a resource recipient, the provisions of ASU 2018-08 are effective for fiscal years beginning after June 15, 2018 and interim periods within those years, for public business entities and not-for-profit entities, and December 15, 2018 for all other entities. When the entity is a resource provider, the provisions of ASU 2018-08 are effective for fiscal years beginning after December 15, 2018 and interim periods within those years, for public business entities and not-for-profit entities, and December 15, 2019 for all other entities. This ASU is not expected to have a material impact on the combined financial statements.

In August 2018, FASB issued ASU 2018-13, “*Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement*.” The amendments in ASU 2018-13 remove certain disclosure requirements related to transfers between fair value levels, the valuation of Level 3 assets and liabilities, as well as the changes in unrealized gains and losses included in earnings for Level 3. Additionally, these amendments modify certain disclosure requirements related to transfers, purchases, and issuances in and out of Level 3 for nonpublic entities. The provisions of ASU 2018-13 are effective for fiscal years beginning after December 15, 2019 and interim periods within those years. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The System is currently evaluating the impact of this ASU.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

In August 2018, FASB issued ASU 2018-14, “*Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans.*” The amendments in ASU 2018-14 remove certain requirements related to the amount and timing of plan assets expected to be returned to the employer, related party disclosures, and disclosures related to Level 3 fair value. Additionally, these amendments clarify and enhance the disclosures for projected benefit obligation and accumulated benefit obligation. The provisions of ASU 2018-14 are effective for fiscal years ending after December 15, 2020, for public business entities and December 15, 2021, for all other entities. The System is currently evaluating the impact of this ASU.

In August 2018, FASB issued ASU 2018-15, “*Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.*” The amendments in ASU 2018-15 determine which implementation costs to capitalize as an asset and which costs to expense. Additionally, these amendments clarify how the capitalized implementation costs should be presented within the financial statements. The provisions of ASU 2018-15 are effective for fiscal years ending after December 15, 2019, for public business entities and December 15, 2020, for all other entities. The System is currently evaluating the impact of this ASU.

Cash and Cash Equivalents

Cash equivalents are defined as investments which have original maturities of three months or less. Cash equivalents consist primarily of securities issued by the United States government or its agencies, certificates of deposit, commercial paper, and dollar denominated foreign issuer investments.

THVG Funds Due From United Surgical Partners, Inc.

THVG participates in a shared services accounts payable program with USPI, wherein USPI has custody of substantially all of THVG’s cash, paying THVG and its facilities interest income on the net balance at prevailing market rates. Amounts held by USPI on behalf of THVG totaled approximately \$117,029,000 and \$117,752,000, at December 31, 2018 and June 30, 2018, respectively. The funds due from USPI are available on demand.

Investments

The System has designated all of its investments as trading except for those investments held at Highground Advisors (HA) for the benefit of the BHCS Foundation and the investments of All Saints Health Foundation. For all trading investments, the interest and dividends, realized gains (losses) and unrealized gains (losses) are included in gains (losses) on investments, net,

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

in the accompanying combined statements of operations and changes in net assets. For other than trading investments, interest and dividends and realized gains (losses) are included in gains (losses) on investments, net, unless restricted by donor. Unrealized gains (losses) on other than trading investments are included in other changes in unrestricted net assets, unless restricted by donor.

Interest and dividends, realized gains, and unrealized (losses) gains consisted of the following (in thousands):

	Six months ended December 31, 2018			
	Interest and Dividends	Realized Gains	Unrealized Losses	Total
Nonoperating gains (losses)	\$ 32,328	\$ 32,653	\$ (186,223)	\$ (121,242)
Other changes in unrestricted net assets	-	-	(575)	(575)
Changes in temporarily restricted net assets	8,065	5,606	(25,131)	(11,460)
Changes in permanently restricted net assets	-	699	(651)	48
	\$ 40,393	\$ 38,958	\$ (212,580)	\$ (133,229)

	Six months ended December 31, 2017			
	Interest and Dividends	Realized Gains	Unrealized Gains (Losses)	Total
Nonoperating gains	\$ 28,610	\$ 44,843	\$ 114,101	\$ 187,554
Other changes in unrestricted net assets	-	-	(2,344)	(2,344)
Changes in temporarily restricted net assets	4,703	8,764	12,797	26,264
Changes in permanently restricted net assets	-	542	(83)	459
	\$ 33,313	\$ 54,149	\$ 124,471	\$ 211,933

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

	Year ended June 30, 2018			
	Interest and Dividends	Realized Gains	Unrealized Gains (Losses)	Total
Nonoperating gains	\$ 55,588	\$ 90,597	\$ 70,305	\$ 216,490
Other changes in unrestricted net assets	-	-	(2,688)	(2,688)
Changes in temporarily restricted net assets	9,451	14,104	10,042	33,597
Changes in permanently restricted net assets	-	2,333	(122)	2,211
	\$ 65,039	\$ 107,034	\$ 77,537	\$ 249,610

	Year ended June 30, 2017			
	Interest and Dividends	Realized Gains	Unrealized Gains (Losses)	Total
Nonoperating gains	\$ 37,371	\$ 95,293	\$ 138,667	\$ 271,331
Other changes in unrestricted net assets	-	-	(1,786)	(1,786)
Changes in temporarily restricted net assets	7,615	9,754	18,562	35,931
Changes in permanently restricted net assets	-	175	370	545
	\$ 44,986	\$ 105,222	\$ 155,813	\$ 306,021

3. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value measurements

As defined in ASC 820, “*Fair Value Measurements*”, fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy for disclosure of fair value measurements.

The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

- Level 1 - Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 - Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable by market participants for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

- Level 3 - Inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability are unobservable and developed based on the best information available in the circumstances.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The carrying values of cash and cash equivalents, THVG funds due from USPI, patient accounts receivable, other receivables, investments of insurance subsidiaries, accounts payable, accrued liabilities, and estimated third-party payor settlements payable are reasonable estimates of their fair value due to the short-term nature of these financial instruments.

Fair values of short-term investments and long-term investments are generally based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers. This applies to investments such as domestic equities, U.S. treasuries, exchange-traded mutual funds, and agency securities.

Alternative Investments

Investments held consist of marketable securities as well as securities that do not have readily determinable fair values. Private equity investments, real estate investments, and hedge funds are collectively referred to as "alternative investments." These are included in unrestricted long-term investments in the accompanying combined balance sheets, other than those held at HA. The investments in alternative investments are valued by management at fair value utilizing the net asset value (NAV) provided by the underlying investment companies unless management determines some other valuation is more appropriate. Such fair value estimates do not reflect early redemption penalties as the System does not intend to sell such investments before the expiration of the early redemption periods. The fair values of the securities held by limited partnerships that do not have readily determinable fair values are determined by the general partner and are based on historical cost, appraisals, or other estimates that require varying degrees of judgment. If no public market exists for the investment securities, the fair value is determined by the general partner taking into consideration, among other things, the cost of securities, prices of recent significant placements of securities of the same issuer, and subsequent developments concerning the companies to which the securities relate. Investments valued at NAV are not leveled within the fair value hierarchy.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

Included in collective investment funds held at HA for the BHCS Foundation are alternative investment interests in private equity funds and oil and gas interests. These interests are included in restricted long-term investments in the accompanying combined balance sheets. These alternative investments are in limited partnership interests and are carried at the NAV provided by the underlying investment companies unless management determines some other valuation is more appropriate. BHCS Foundation also has other real estate and oil and gas interests which are carried at lower of cost or market and represent Level 3 assets.

Beneficial Interest

The System records charitable remainder trusts, where it is not the trustee, at the discounted present value of the estimated future cash flows. These trusts are reported in contributions receivable, net, in the accompanying combined balance sheets. When a third-party serves as trustee, the beneficial interest is required to be measured at fair value on a recurring basis. As beneficial interests utilize multiple unobservable inputs, including no active markets, and are measured using management's assumption about risk inherent in the valuation technique, beneficial interests in split-interest agreements represent Level 3 assets.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the System believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

The following table below sets forth, by level, the financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 (in thousands):

Assets:	December 31, 2018			
	Total	Level 1	Level 2	Level 3
Cash and cash equivalents				
Cash	\$ 914,424	\$ 914,424	\$ -	\$ -
Money market funds	32,388	32,388	-	-
Total cash and cash equivalents	946,812	946,812	-	-
Short-term investments				
Cash	44	44	-	-
Mutual funds	1,308	1,308	-	-
Fixed income securities	1,822	-	1,822	-
U.S. government securities	125,261	97,105	28,156	-
Other	65,227	65,151	76	-
Total short-term investments	193,662	163,608	30,054	-
Unrestricted long-term investments				
Cash	1,642	1,642	-	-
Certificates of deposit	500	500	-	-
Mutual funds	31,345	31,275	70	-
Equity securities	1,515,389	280,128	1,235,261	-
Fixed income securities	241,900	28	241,872	-
U.S. government securities	486,464	-	486,464	-
Mortgage-backed securities	381,389	65,528	315,861	-
Split-interest agreements	1,153	-	1,153	-
Cash surrender value life insurance	663	-	-	663
Other	754	-	716	38
Common funds, held at HA				
Group investment fund	598	-	598	-
Group bond fund	35	-	35	-
Group equity fund	67	-	67	-
Other funds	21	20	-	1
Assets held at NAV practical expedient ⁽¹⁾				
Hedge fund/diversifiers alternative investments	510,957			
Private equity alternative investments	228,641			
Real estate alternative investments	114,734			
Other funds	4			
Total unrestricted long-term investments	3,516,256	379,121	2,282,097	702

(1) Hedge fund/diversifiers alternative investments, private equity alternative investments, real estate alternative investments, and other investments for which fair value is measured using the NAV per share as a practical expedient are not leveled within the fair value hierarchy and are included as a reconciling item to total investments.

In the accompanying combined balance sheets, unrestricted long-term investments at December 31, 2018 includes an investment of approximately \$128,947,000 accounted for under the cost method.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

Assets (continued):	December 31, 2018			
	Total	Level 1	Level 2	Level 3
Restricted long-term investments				
Cash	\$ 6,192	\$ 6,192	\$ -	\$ -
Mutual funds	45,051	44,887	164	-
Equity securities	191,088	41,283	149,805	-
Fixed income securities	15,113	65	15,048	-
U.S. government securities	23,514	-	23,514	-
Mortgage-backed securities	27,647	4,847	22,800	-
Split-interest agreements	4,815	-	4,815	-
Real estate	257	-	-	257
Cash surrender value life insurance	1,143	-	-	1,143
Other	1	1	-	-
Common funds, held at HA				
Group investment fund	45,062	-	45,062	-
Group bond fund	2,610	-	2,610	-
Group equity fund	5,039	-	5,039	-
Other funds	1,551	1,497	-	54
Assets held at NAV practical expedient ⁽¹⁾				
Hedge fund/diversifiers alternative investments	66,194			
Private equity alternative investments	42,724			
Real estate alternative investments	10,549			
Other funds	286			
Total restricted long-term investments	488,836	98,772	268,857	1,454
Assets Whose Use is Limited				
Cash	29,775	29,775	-	-
Money market funds	5,973	5,973	-	-
Mutual funds	193,082	193,082	-	-
Equity securities	1,477	1,477	-	-
Fixed income securities	19,381	-	19,381	-
U.S. government securities	37,396	-	37,396	-
Other	164	164	-	-
Total assets whose use is limited	287,248	230,471	56,777	-
Contributions receivable, net				
Beneficial interest in split-interest agreements	24,821	-	-	24,821
Total assets at fair value	\$ 5,457,635	\$ 1,818,784	\$ 2,637,785	\$ 26,977
Liabilities:				
Interest rate swap agreements, net of collateral	228,455	-	228,455	-
Total liabilities at fair value	\$ 228,455	\$ -	\$ 228,455	\$ -

(1) Hedge fund/diversifiers alternative investments, private equity alternative investments, real estate alternative investments, and other investments for which fair value is measured using the NAV per share as a practical expedient are not leveled within the fair value hierarchy and are included as a reconciling item to total investments.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

The following table is a roll forward of the combined balance sheet amounts for financial instruments classified by the System within Level 3 of the valuation hierarchy defined above for the six months ended December 31, 2018 (in thousands):

	December 31, 2018			
	Common		Other	Total
	Split-Interest Agreements	Investment Funds		
Balance, beginning of period	\$ 24,584	\$ 55	\$ 2,182	\$ 26,821
Realized gains (losses), net	60	-	(77)	(17)
Unrealized (losses) gains, net	(494)	-	1	(493)
Purchases	768	-	-	768
Settlements	(97)	-	(5)	(102)
Balance, end of period	\$ 24,821	\$ 55	\$ 2,101	\$ 26,977

At December 31, 2018, alternative investments recorded at NAV consisted of the following (in thousands):

	December 31, 2018			
	Fair Value	Unfunded Commitments	Redemption Frequency if Currently Eligible	Redemption Notice Period
Equity-linked investments ^a	\$ 49,114	\$ -	quarterly, annually	60-90 days
Event-driven investments ^b	84,433	-	quarterly, annually	30-90 days
Credit-linked investments ^c	84,421	-		
Multi-strategy investments ^d	1,957	-	monthly, quarterly	30-90 days
Tactical trading investments ^e	146,849	-	daily, monthly	2-90 days
Risk parity and global asset allocation fund ^f	210,377	-	monthly	5-30 days
Real estate funds - open ended ^g	55,795	-	quarterly	90 days
Real estate funds - closed ended ^h	69,488	21,819		
Oil and gas funds ⁱ	290	-		
Private equity funds ^j	203,575	192,488		
Private debt funds ^k	67,790	43,652		
Total	\$ 974,089	\$ 257,959		

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

- a) Equity-linked fund managers buy equities that are expected to increase in value and sell short equities that are expected to decrease in value. Portfolios range from net short to net long, depending on market conditions. Aggressive funds may capture returns by exceeding 100% exposure while conservative funds mitigate market risk by maintaining net exposures of between 0-50%. Typically, equity-linked strategies are based on "bottom up" fundamental analysis of the individual companies, in which investments are made. There may also be "top down" analysis of the risks and opportunities offered by industries, sectors, countries, and the macroeconomic situation. Equity-linked managers may be generalists or focus on certain industries, sectors, regions or equity category (i.e. small or large cap and value or growth). There are many trading styles, with frequent or dynamic traders and some longer-term investors. Returns are generally more correlated with the direction of the equity markets, although reduction in market risk exposure through shorting is expected to enhance the absolute and risk-adjusted returns relative to the overall performance of the asset class. The fair values of the investments in this class have been estimated using the net asset value per share of the funds.
- b) Event-driven fund managers seek to exploit pricing inefficiencies that may occur before or after corporate events such as an earnings announcement, bankruptcy, merger, acquisition, or spinoff. Returns are less correlated with the general direction of market movements primarily due to the idiosyncratic nature of individual events. Several investment managers include quarterly percentage redemption limits. The fair values of the investments in this class have been estimated using the net asset value per share of the funds.
- c) Credit-linked fund managers seek to profit from the mispricing of related securities. These strategies utilize quantitative and qualitative analysis to identify securities or spreads between securities that deviate from their fair value and/or historical norms. Examples include convertible arbitrage, fixed arbitrage, statistical arbitrage, and select global macro strategies. Fund returns are generally not dependent on the direction of market movements. The fair values of the investments in this class have been estimated using the net asset value per share of the funds.
- d) Multi-strategy fund managers focus on large, long-term mispricing in the global fixed-income, equity and credit markets, capturing relative-value anomalies via multi-product trades. Returns are relatively uncorrelated with the general direction of market movements since they avoid taking a directional bias with regards to the price movement of a specific stock or market. Several investment managers include quarterly percentage redemption limits and/or early redemption penalties. The fair values of the investments in this class have been estimated using the net asset value per share of the funds.
- e) Tactical trading fund managers generally invest on a large scale around the world using economic theory to justify the decision making process on either a discretionary or systematic basis. Strategies are typically based on forecasts and analysis about interest rate

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

trends, the general flow of funds, political changes, government policies, inter-government relations, and other broad systemic and technical factors. Returns are relatively uncorrelated with the general direction of market movements. Several investment managers include quarterly percentage redemption limits. The fair values of the investments in this class have been estimated using the net asset value per share of the funds.

- f) Risk parity and global asset allocation fund managers invest across global markets including equities, nominal government bonds, inflation linked bonds, commodities, and emerging markets on a risk balanced framework. Typically these strategies incorporate leverage to increase the risk contribution from low volatility asset classes (e.g., inflation linked bonds and nominal government bonds). The fair values of the investments in this class have been estimated using the net asset value per share of the funds.
- g) Real estate - open end fund managers invest in U.S. commercial real estate. Redemptions are available on a quarterly basis, subject to the discretion of the General Partners. The General Partners may elect to establish a redemption queue should the level of redemptions for a given quarter be detrimental to the fund's overall performance. The fair values of the investments in this class have been estimated using the net asset value, which is based on the ownership interest of partners' capital.
- h) Real estate - closed end fund managers invest primarily in U.S. commercial real estate and industries related to real estate, with some having minimal exposure outside of the U.S. These partnerships are illiquid and therefore do not have a redemption feature. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of these funds will be liquidated over the next six years with the value of those underlying asset being replaced by investments in new real estate funds. The fair values of the investments in this class have been estimated using the net asset value, which is based on the ownership interest of partners' capital.
- i) Oil and gas fund managers invested in mineral properties located in Texas and Wyoming. The fund in this category is closed to new investors, is illiquid and redemption is subject to fund management approval. Royalty income is distributed quarterly subject to fund management approval (\$0.50 per unit per quarter in 2018 and 2017). Distributions from the fund will be received as the underlying investments are depleted. The fair value of the mineral properties have been estimated by multiplying the most recent twelve months of royalty income, excluding lease bonus income, times a factor of five. The fund's management used a multiple of five for the valuation based on current industry methodology, recent market transactions, and the fund's extensive experience in mineral properties.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

- j) Thirty - seven private equity fund managers invest in a variety of mostly private companies. These investments have a drawdown structure where a portion of commitments (which are made upon entering the partnership) are called gradually over the first 3-6 years of the partnership's life. It is expected that most of the unfunded commitments should be called within the next 6 years. These partnerships are illiquid and therefore do not have a redemption feature. Instead, the nature of the investments in this class is that distributions are received as the investment in the underlying companies are sold. It is estimated that the current underlying assets of these partnerships should be liquidated within the next 10 years. The investments are valued based on each partnership's valuation policy which is then subject to annual third party financial audits. Financial audits are available approximately 90 days following year end. Therefore, the valuation at year end reflects the latest reported manager valuation with adjustments for new capital calls and distributions.
- k) Seven private debt fund managers invest in a variety of mostly private companies. These investments have a drawdown structure where a portion of commitments (which are made upon entering the partnership) are called gradually over the first 1-3 years of the partnership's life. It is expected that most of the unfunded commitments should be called within the next 4 years. These partnerships are illiquid and therefore do not have a redemption feature. Instead, the nature of the investments in this class is that distributions are received as income from the debt is received and as the investment in the underlying companies are sold or the debt principal is repaid. It is estimated that the current underlying assets of these partnerships should be liquidated within the next 6 years. The investments are valued based on each partnership's valuation policy which is then subject to annual third party financial audits. Financial audits are available approximately 90 days following year end. Therefore, the valuation at year end reflects the latest reported manager valuation with adjustments for new capital calls and distributions.

4. ENDOWMENTS

The System's endowments consist of donor-restricted and board-designated endowment funds for a variety of purposes. The net assets associated with endowment funds are classified and reported based on the existence or absence of donor imposed restrictions.

The System has interpreted the State of Texas Uniform Prudent Management of Institutional Funds Act (UPMIFA) as not requiring the maintaining of purchasing power of permanently restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the System classifies as permanently restricted net assets, (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the System in a manner consistent with the standard of prudence prescribed by UPMIFA.

In accordance with UPMIFA, the System considers the following factors in making a determination to appropriate or accumulate endowment funds:

- 1) The duration and preservation of the fund
- 2) The purposes of the System and the donor restricted endowment fund
- 3) General economic conditions
- 4) The possible effect of inflation and deflation
- 5) The expected total return from income and the appreciation of investments
- 6) Other resources of the System and
- 7) The investment policies of the System

Endowment Return Objectives and Risk Parameters

The System follows an investment policy that attempts to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to maximize the return against various indices, based on the endowment's target allocation applied to the appropriate individual benchmarks.

To achieve its long-term rate of return objectives, the System relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The System targets a diversified asset allocation that places greater emphasis on equity-based investments to achieve its long-term objectives within prudent risk constraints.

Relationship of Endowment Spending Practices to Investment Objectives

The System determines the appropriation of endowment funds for expenditure reimbursement through the budgeting process. Distribution policies for the System's endowments govern the amount of endowment funds that may be appropriated during this process. In establishing its policies, the System considered the long-term expected return on its endowments. Accordingly, over the long-term, the System expects the current distribution policies to allow its endowments to grow at an average of the long-term rate of inflation and maintain its purchasing power. In order to maintain the purchasing power of endowment assets, expenditures are based on investment performance and spending is curbed in response to deficit situations. Over the long-term, the System expects its endowment to grow consistent with its intention to maintain the purchasing power of the endowment assets as well as to provide additional real growth through new gifts.

Quarterly Disclosure Report for December 31, 2018

Notes to Combined Financial Statements - continued

5. RETIREMENT BENEFITS

The System provides 401(k) defined contribution plans for eligible employees. Employees are eligible to contribute to the plans immediately with no minimum service or age requirement.

The System had four frozen defined benefit plans at the time of merger. Three of the four plans are subject to ERISA and all are being funded in accordance with regulatory requirements. Three of the four plans were merged together in fiscal year 2017.

6. CONTINGENCIES

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, physician ownership and self-referral, and Medicare and Medicaid fraud and abuse. Government activity has continued with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the System is in compliance with applicable fraud and abuse laws and regulations as well as other applicable federal and state laws and regulations.

7. SUBSEQUENT EVENTS

FirstCare Health Plans

On January 1, 2019, the Health Plan acquired SHA, LLC d/b/a FirstCare Health Plans and its subsidiary, Southwest Life & Health Insurance Company, from Covenant Health System in Lubbock, Texas and Hendrick Health System in Abilene, Texas.

Letter of Intent with Memorial Hermann

On September 28, 2018, BSWH executed a letter of intent with Memorial Hermann Health System to pursue merging the operations of the two health systems through the creation of a new nonprofit, tax-exempt parent corporation. On February 5, 2019, BSWH and MHHS announced merger discussions have been discontinued.

The System has performed an evaluation of material subsequent events and transactions from December 31, 2018 through February 14, 2019.

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health Supplementary Combining Financial Information of the Obligated Affiliates and BSWH Combining Balance Sheets December 31, 2018 (\$ Thousands)					
ASSETS	Obligated Affiliates *	Consolidated Health Plan †	Other System Entities	Reclassifications and Eliminations	Total Financials
CURRENT ASSETS:					
Cash and cash equivalents	\$ 444,703	\$ 88,468	\$ 412,655	\$ 986	\$ 946,812
Short-term investments	172,618	4,671	16,329	44	193,662
THVG funds due from United Surgical Partners, Inc.	-	-	117,029	-	117,029
Accounts receivable:					
Patient, net	491,845	-	403,445	(29,292)	865,998
Premium	-	86,606	-	-	86,606
Affiliates, net	7,637	-	-	(7,637)	-
Other	84,328	18,898	88,740	(9,502)	182,464
Other current assets	227,699	91,640	101,197	-	420,536
Total current assets	<u>1,428,830</u>	<u>290,283</u>	<u>1,139,395</u>	<u>(45,401)</u>	<u>2,813,107</u>
LONG-TERM INVESTMENTS:					
Unrestricted	3,057,435	110,976	477,822	(1,030)	3,645,203
Restricted	2,413	-	486,423	-	488,836
Total long-term investments	<u>3,059,848</u>	<u>110,976</u>	<u>964,245</u>	<u>(1,030)</u>	<u>4,134,039</u>
ASSETS WHOSE USE IS LIMITED:					
Other designated assets	125,570	2,200	17,738	-	145,508
Self insurance reserves	-	-	123,530	-	123,530
Funds held by bond trustee	18,210	-	-	-	18,210
Total assets whose use is limited	<u>143,780</u>	<u>2,200</u>	<u>141,268</u>	<u>-</u>	<u>287,248</u>
PROPERTY AND EQUIPMENT, net	2,664,347	15,086	1,300,406	(211,660)	3,768,179
CONTRIBUTIONS RECEIVABLE, net	4,506	-	174,051	(52)	178,505
DUE FROM AFFILIATES	293,794	-	1,707	(295,501)	-
INTEREST IN NET ASSETS OF RELATED FOUNDATIONS	553,587	-	106,716	(656,086)	4,217
INVESTMENTS IN SUBSIDIARIES AND AFFILIATES	1,978,630	-	-	(1,978,630)	-
OTHER LONG-TERM ASSETS:					
Equity investment in unconsolidated entities	39,478	253	21,922	-	61,653
Goodwill and intangible assets, net	89,601	-	791,278	(2,412)	878,467
Other	9,353	1,829	10,737	(6,992)	14,927
Total other long-term assets	<u>138,432</u>	<u>2,082</u>	<u>823,937</u>	<u>(9,404)</u>	<u>955,047</u>
Total assets	<u>\$ 10,265,754</u>	<u>\$ 420,627</u>	<u>\$ 4,651,725</u>	<u>\$ (3,197,764)</u>	<u>\$ 12,140,342</u>

*Obligated Affiliates combines Baylor Health Care System; Baylor University Medical Center; Baylor All Saints Medical Center; Baylor Medical Center at Waxahachie; Baylor Regional Medical Center at Grapevine; Baylor Medical Center at Plano; Scott & White Healthcare; Scott & White Memorial Hospital (inclusive of McLane Children's Hospital Scott & White); Scott & White Clinic; Scott & White Hospital - Round Rock; Scott & White Continuing Care Hospital; Hillcrest Baptist Medical Center; Baylor Scott & White Holdings; Baylor Scott & White Health; Baylor Medical Centers at Garland and McKinney; and Scott & White Hospital - College Station.

† Consolidated Health Plan includes Scott and White Health Plan and Insurance Company of Scott and White.

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health					
Supplementary Combining Financial Information of the Obligated Affiliates and BSWH					
Combining Balance Sheets - continued					
December 31, 2018					
(\$ Thousands)					
LIABILITIES AND NET ASSETS	<u>Obligated Affiliates *</u>	<u>Consolidated Health Plan †</u>	<u>Other System Entities</u>	<u>Reclassifications and Eliminations</u>	<u>Total Financials</u>
CURRENT LIABILITIES:					
Current maturities of long-term debt and capital lease obligations	\$ 19,953	\$ -	\$ 42,349	\$ -	\$ 62,302
Long-term debt subject to short-term remarketing arrangements	95,000	-	-	-	95,000
Commercial paper	207,438	-	-	-	207,438
Accounts payable:					
Trade accounts payable	140,598	7,348	196,783	(13,498)	331,231
Affiliates, net	-	10,774	1,189	(11,963)	-
Accrued liabilities:					
Payroll related	282,407	113	71,787	-	354,307
Third-party programs	20,033	14,084	11,036	35,798	80,951
Medical claims payable	-	92,469	-	(65,090)	27,379
Other	271,407	67,677	161,609	(18,694)	481,999
Total current liabilities	1,036,836	192,465	484,753	(73,447)	1,640,607
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS, less current maturities	2,666,287	-	454,753	-	3,121,040
OTHER LONG-TERM LIABILITIES:					
Self insurance and other insurance liabilities	(1,455)	-	123,530	-	122,075
Interest rate swap liabilities, net	228,455	-	-	-	228,455
Other	183,282	12,973	115,157	(5,668)	305,744
Total other long-term liabilities	410,282	12,973	238,687	(5,668)	656,274
DUE TO AFFILIATES	-	-	424,148	(424,148)	-
Total liabilities	4,113,405	205,438	1,602,341	(503,263)	5,417,921
COMMITMENTS AND CONTINGENCIES					
NONCONTROLLING INTERESTS - REDEEMABLE	-	-	325,776	123,801	449,577
NET ASSETS:					
Unrestricted - attributable to BSWH	5,585,974	215,189	1,888,934	(2,391,106)	5,298,991
Unrestricted - noncontrolling interests - nonredeemable	22,184	-	55,518	217,070	294,772
Total unrestricted net assets	5,608,158	215,189	1,944,452	(2,174,036)	5,593,763
Temporarily restricted	333,555	-	454,569	(389,491)	398,633
Permanently restricted	210,636	-	324,587	(254,775)	280,448
Total net assets	6,152,349	215,189	2,723,608	(2,818,302)	6,272,844
Total liabilities and net assets	\$ 10,265,754	\$ 420,627	\$ 4,651,725	\$ (3,197,764)	\$ 12,140,342

*Obligated Affiliates combines Baylor Health Care System; Baylor University Medical Center; Baylor All Saints Medical Center; Baylor Medical Center at Waxahachie; Baylor Regional Medical Center at Grapevine; Baylor Medical Center at Plano; Scott & White Healthcare; Scott & White Memorial Hospital (inclusive of McLane Children's Hospital Scott & White); Scott & White Clinic; Scott & White Hospital - Round Rock; Scott & White Continuing Care Hospital; Hillcrest Baptist Medical Center; Baylor Scott & White Holdings; Baylor Scott & White Health; Baylor Medical Centers at Garland and McKinney; and Scott & White Hospital - College Station.

† Consolidated Health Plan includes Scott and White Health Plan and Insurance Company of Scott and White.

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health					
Supplementary Combining Financial Information of the Obligated Affiliates and BSWH					
Combining Statements of Operations and Changes in Net Assets					
For the Six Months Ended December 31, 2018					
(\$ Thousands)					
	Obligated Affiliates *	Consolidated Health Plan †	Other System Entities	Reclassifications and Eliminations	Total Financials
OPERATING REVENUE:					
Net patient care revenue	\$ 2,477,198	\$ -	\$ 2,015,946	\$ (193,415)	\$ 4,299,729
Premium revenue	-	397,850	-	(232)	397,618
Other operating revenue	233,885	8,153	293,979	(356,984)	179,033
Net assets released from restrictions for operations	4,270	-	34,174	(5,407)	33,037
Total operating revenue	<u>2,715,353</u>	<u>406,003</u>	<u>2,344,099</u>	<u>(556,038)</u>	<u>4,909,417</u>
OPERATING EXPENSES:					
Salaries, wages, and employee benefits	1,354,952	21,585	901,811	(24,574)	2,253,774
Supplies	412,587	66	432,932	-	845,585
Other operating expenses	619,384	39,902	673,697	(342,674)	990,309
Medical claims	-	342,441	-	(197,469)	144,972
(Gains) losses on fixed asset sales and disposals, net	(1,073)	-	234	-	(839)
Depreciation and amortization	131,409	255	67,512	(3,885)	195,291
Interest	50,480	1,236	21,596	(8,744)	64,568
Total operating expenses	<u>2,567,739</u>	<u>405,485</u>	<u>2,097,782</u>	<u>(577,346)</u>	<u>4,493,660</u>
Income from operations	<u>147,614</u>	<u>518</u>	<u>246,317</u>	<u>21,308</u>	<u>415,757</u>
NONOPERATING GAINS (LOSSES):					
Losses on investments, net	(96,236)	(1,213)	(18,713)	(5,080)	(121,242)
Interest rate swap activity	(18,213)	-	-	-	(18,213)
Contributions	13,699	-	243	(13,941)	1
Equity in gains (losses) of unconsolidated entities	371	-	(230)	-	141
Loss from extinguishment of debt	(200)	-	-	-	(200)
Other	103,360	(6)	7,416	(110,701)	69
Total nonoperating gains (losses)	<u>2,781</u>	<u>(1,219)</u>	<u>(11,284)</u>	<u>(129,722)</u>	<u>(139,444)</u>
REVENUE AND GAINS IN EXCESS (DEFICIT) OF EXPENSES AND LOSSES BEFORE TAXES					
	150,395	(701)	235,033	(108,414)	276,313
LESS INCOME TAX EXPENSE					
	<u>385</u>	<u>8</u>	<u>8,256</u>	<u>-</u>	<u>8,649</u>
REVENUE AND GAINS IN EXCESS (DEFICIT) OF EXPENSES AND LOSSES					
	150,010	(709)	226,777	(108,414)	267,664
*Obligated Affiliates combines Baylor Health Care System; Baylor University Medical Center; Baylor All Saints Medical Center; Baylor Medical Center at Waxahachie; Baylor Regional Medical Center at Grapevine; Baylor Medical Center at Plano; Scott & White Healthcare; Scott & White Memorial Hospital (inclusive of McLane Children's Hospital Scott & White); Scott & White Clinic; Scott & White Hospital - Round Rock; Scott & White Continuing Care Hospital; Hillcrest Baptist Medical Center; Baylor Scott & White Holdings; Baylor Scott & White Health; Baylor Medical Centers at Garland and McKinney; and Scott & White Hospital - College Station.					
† Consolidated Health Plan includes Scott and White Health Plan and Insurance Company of Scott and White.					

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health

Supplementary Combining Financial Information of the Obligated Affiliates and BSWH

Combining Statements of Operations and Changes in Net Assets - continued

For the Six Months Ended December 31, 2018

(\$ Thousands)

	Obligated Affiliates *	Consolidated Health Plan †	Other System Entities	Reclassifications and Eliminations	Total Financials
OTHER CHANGES IN UNRESTRICTED NET ASSETS:					
Unrealized losses on investments, net	\$ -	\$ -	\$ (575)	\$ -	\$ (575)
Net assets released from restrictions for capital expenditures	115	-	16,365	8	16,488
Other changes in net assets attributable to noncontrolling interests - nonredeemable	(699)	-	(169,686)	132,974	(37,411)
Revenue and gains in excess of expenses and losses attributable to noncontrolling interests - redeemable	-	-	(112,959)	(37,768)	(150,727)
Transfers between entities under common control	(8,569)	89,999	18,431	(99,861)	-
Net assets acquired	-	-	6,955	-	6,955
Other	1	-	(549)	(2,129)	(2,677)
INCREASE (DECREASE) IN UNRESTRICTED NET ASSETS	140,858	89,290	(15,241)	(115,190)	99,717
CHANGES IN TEMPORARILY RESTRICTED NET ASSETS:					
Contributions	3,205	-	40,059	(5,399)	37,865
Realized investment income	-	-	13,671	-	13,671
Unrealized losses on investments	-	-	(25,131)	-	(25,131)
Change in value of split-interest agreements	(8)	-	(577)	-	(585)
Net assets released from restrictions for operations	(4,270)	-	(34,174)	5,407	(33,037)
Net assets released from restrictions for capital expenditures	(115)	-	(16,365)	(8)	(16,488)
Other	21	-	210	-	231
DECREASE IN TEMPORARILY RESTRICTED NET ASSETS	(1,167)	-	(22,307)	-	(23,474)
CHANGES IN PERMANENTLY RESTRICTED NET ASSETS:					
Contributions	-	-	3,441	-	3,441
Realized investment income	-	-	699	-	699
Unrealized losses on investments	-	-	(651)	-	(651)
Change in value of split-interest agreements	(55)	-	(388)	3	(440)
Other	-	-	(186)	-	(186)
(DECREASE) INCREASE IN PERMANENTLY RESTRICTED NET ASSETS	(55)	-	2,915	3	2,863
INCREASE (DECREASE) IN NET ASSETS	139,636	89,290	(34,633)	(115,187)	79,106
NET ASSETS, beginning of period	6,012,713	125,899	2,758,241	(2,703,115)	6,193,738
NET ASSETS, end of period	\$ 6,152,349	\$ 215,189	\$ 2,723,608	\$ (2,818,302)	\$ 6,272,844

*Obligated Affiliates combines Baylor Health Care System; Baylor University Medical Center; Baylor All Saints Medical Center; Baylor Medical Center at Waxahachie; Baylor Regional Medical Center at Grapevine; Baylor Medical Center at Plano; Scott & White Healthcare; Scott & White Memorial Hospital (inclusive of McLane Children's Hospital Scott & White); Scott & White Clinic; Scott & White Hospital - Round Rock; Scott & White Continuing Care Hospital; Hillcrest Baptist Medical Center; Baylor Scott & White Holdings; Baylor Scott & White Health; Baylor Medical Centers at Garland and McKinney; and Scott & White Hospital - College Station.

† Consolidated Health Plan includes Scott and White Health Plan and Insurance Company of Scott and White.

Quarterly Disclosure Report for December 31, 2018

Baylor Scott & White Health

Obligated Affiliates - Combined Statement of Cash Flows

For the Six Months Ended December, 2018

(\$ Thousands)

Cash Flows from Operating Activities:

Increase in net assets	\$ 139,636
Adjustments to reconcile increase in net assets to net cash provided by operating activities:	
Loss on extinguishment of debt	200
Unrealized losses on investments, net	149,397
Realized gains on sales of investments, net	(25,027)
Gains on interest rate swap, net	8,752
Depreciation and amortization	131,409
Gains on fixed asset sales and disposals, net	(1,073)
Change in value of split-interest agreements	63
Transfers between entities under common control	8,569
Other changes attributable to noncontrolling interests	699
Changes in operating assets and liabilities (net of acquisitions):	
Increase in net patient accounts receivable	(14,642)
Decrease in other accounts receivable	9,474
Decrease in other assets	8,511
Increase in affiliates receivable, net and due from affiliates, net	(72,917)
Decrease in trade accounts payable and accrued liabilities	(91,527)
Increase in other liabilities	19,877
Net cash provided by operating activities	271,401

Cash Flows from Investing Activities:

Purchases of property and equipment, net	(140,208)
Cash proceeds from sales of assets	1,118
Decrease in investments, net	(268,545)
Net payments on interest rate swap	(9,977)
Increase in investments of subsidiaries	(109,515)
Decrease in assets whose use is limited	15,293
Net cash used in investing activities	(511,834)

Cash Flows from Financing Activities:

Principal payments on long-term debt	(34,856)
Proceeds from issuance of long-term debt	19,464
Transfers between entities under common control	(8,569)
Sale of noncontrolling interests	(699)
Net cash used in financing activities	(24,660)

Net Decrease in Cash and Cash Equivalents	(265,093)
Cash and Cash Equivalents, beginning of period	709,796
Cash and Cash Equivalents, end of period	\$ 444,703